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Hypertension is endemic worldwide, afflicting up to 40% of the global population over the age of 25. 
Haemodynamic stretch stress from raised blood pressure is a driver for organ damage in the heart and 
kidney, contributing to potentially fatal conditions. Aldosterone activated mineralocorticoid receptors 
have also been shown to contribute to cardiorenal damage in a hypertensive state. This study 
compared the effects of spironolactone, a mineralocorticoid receptor antagonist (MRA), and 
amlodipine, a calcium channel blocker, when administered in a chronic hypertensive Cyp1a1-Ren2 
transgenic rat model. Cyp1a1-Ren2 rats characteristically develop hypertension in a dose-dependent 
manner in response to dietary indole-3-carbinol (I3C). Male rats (19 week old) were assigned to either 
standard or I3C (0.167% w/w) diet, 2 weeks prior to experimental day 0. At experimental day 40, rats 
in both dietary groups were assigned into three drug treatment groups (n=4/group): spironolactone 
(8.82 mg/kg/day), amlodipine (0.44 mg/kg/day) or vehicle control oral dosing until termination at 
experimental day 85.  
Systolic blood pressures recorded at day 0 and day 85 were significantly higher in the I3C diet group 
compared to standard diet. Spironolactone and amlodipine did not reduce systolic blood pressure at 
day 85 compared to control groups. Urine volume, proteinuria, left ventricular wall thickness, 
glomerulosclerosis, renal fibrosis and renal populations of both macrophages and myofibroblasts were 
increased in the I3C dietary group compared to standard diet; however none of these variables were 
significantly reduced with either spironolactone or amlodipine treatment compared to the control 
group in the I3C diet group. A reduction in renal fibrosis and renal cortex macrophage infiltration was 
observed with spironolactone treatment compared to control in the I3C diet group; however this was 
not statistically significant. A blood pressure independent reduction in proteinuria was seen in the 
spironolactone treated rats compared to control, but was also not statistically significant.  
The trends identified with spironolactone treatment in this study were consistent with many other 
published works; however these studies suggest spironolactone has been shown to have many other 
protective characteristics unidentified in this study. Internal validity issues arose from initial stress-
related difficulties, compromising intra-group comparisons. This and the underpowered nature of this 
study limit the interpretation of the study’s results. Therefore this study came to no conclusion in 
regards to blood pressure independent benefits of addition of spironolactone to a systemic 
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1.1  Outline 
 
Elevated blood pressure (EBP) is the world’s greatest risk factor for mortality (Alwan, 2011). Death 
results from the vascular, renal and cardiac disease arising secondary to hypertension. The reduction 
of blood pressure through the use of antihypertensives has delivered first class evidence for disease 
reduction (Hansson et al., 1998; Group et al., 2015). Current therapeutic evidence demonstrates that 
hypertensive patients may also benefit from the addition of therapies such as statins and antiplatelets 
which do not directly reduce blood pressure, but control blood-pressure associated pathologies 
(Hansson et al., 1998; Sever et al., 2003). 
In patients with severe heart failure, mineralocorticoid receptor antagonists (MRAs) have been shown 
to reduce mortality in a blood pressure independent effect (Pitt et al., 1999; Pitt et al., 2003b). MRAs 
have also been well established to reduce markers of disease progression in chronic kidney disease 
(CKD) patients (Bolignano et al., 2014). As hypertension is a risk factor for developing both heart 
failure and CKD; the adjunct addition of MRA therapy to standard antihypertensive treatment may 
serve to decrease the progression of cardiorenal hypertensive disease. The aim of this thesis is to 
determine if MRA administration does indeed have a blood pressure independent effect resulting in 
the reduction of cardiac and renal injury, by using a Cyp1a1-Ren2 transgenic rat model of 
hypertension. 
This introduction will initially explore the normal structure and function of cardiac and renal tissue, 
giving context when describing the development and dysfunction of hypertensive pathology. 
Epidemiology, etiology, standard treatment and rat models of hypertension will also be described. 
Mineralocorticoid receptors will be discussed in detail in relation to their physiological role and their 
pathological counterpart. At the end of the introduction chapter the study rationale will be described 
as well as the aims and hypotheses of the described study.   
1.2  The Heart  
1.2.1 Basic Anatomy and Cardiac Cycle  
 
The heart is effectively a double barrel pump which maintains circulation in two circulatory systems; 
the pulmonary and the systemic. There is a ‘right’ and a ‘left’ side of the heart which both consist of 
an atria and a ventricle. The atria act as collecting pools, they continuously receive venous blood; the 
right side collects systemic blood and the left receives pulmonary. As their nomenclature suggests the 
right and left atria feed blood into the right and left ventricle respectively. The ventricles are chambers 
which pump, maintaining circulation. The contractile force generated by their combined myocardial 
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cellular units forces blood out of the ventricle to their respective destinations. The right ventricle 
pumps blood to the lungs, the start of the pulmonary circuit; whereas the left ventricle pumps blood to 
the body, initiating flow in the systemic circuit. The combined vascular resistance of the pulmonary 
circuit is far less than that of the systemic circuit; therefore the force required to ensure circulation in 
the systemic circuit is far greater. The increased thickness of the left ventricular wall in relation to the 
right ventricle reflects this workload.  
The ventricles rhythmically contract and relax, both equally essential functions for maintaining 
circulation. During relaxation, termed diastole, a valve opens between the atria and the ventricle (AV 
valve) allowing the pooled atrial blood to fill the ventricles. At the end of diastole the atria contract to 
maximise ventricular filling volume. During ventricular contraction –systole, the AV valve snaps 
shuts, preventing backflow, and another opens. This freshly opened valve, a semilunar valve, is 
between the ventricle and the main artery of the circulatory system it is supplying; its opening allows 
perfusion of the circulatory system. Over systole the pressure generated by the ventricle falls below 
the pressure in the main artery and the semilunar valve between them closes. The ventricle then starts 
to relax, ending systole and beginning diastole.  
1.2.2  The Myocardium 
 
The muscular wall of the heart is called the myocardium. Both the walls of the atria and ventricles 
consist of myocardium, but wall thickness differences represent the force each chamber needs to 
generate to maintain cardiac function. The atria are thin walled as they have a minimal contractile 
role, whereas the major contractile function of the ventricles is reflected by their thick muscular walls.  
The myocardium is made up of the contractile cells of the heart, the cardiomyocytes, suspended on a 
mesh of connective tissue and interdigitated by vascular tissue.  The contraction of cardiomyocytes as 
a syncytium plays an important role in effective contraction.  Specialised inter-cell connections, called 
gap junctions, ensure electrical conduction to occur between these myocardial cells (de Jong et al., 
2011). A healthy extracellular matrix (ECM) allows effective cell communication. The ECM is the 
connective tissue that supports the cardiomyocytes. Maintaining the correct orientation of 
cardiomyocytes and distribution of capillary networks between the cardiac fibres in the constantly 
mobile myocardium is the core role of the ECM (Berk et al., 2007). The ECM is predominately 
populated by fibroblasts which both degrade and synthesise new components of the matrix, ensuring 
ECM optimum function (Camelliti et al., 2005).  
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1.3  The Kidney 
1.3.1  Nephron Anatomy 
 
The kidney is a complex conglomeration of functional units called nephrons. Studies place the 
average number of nephrons to be one million per kidney, however this varies greatly between 
individuals; numbers are negatively associated with birth weight, blood pressure and renal disease 
(Bertram et al., 2011). The rat kidney comprises of approximately 30000 nephrons (Bennett et al., 
2013). A nephron comprises of a renal corpuscle, which consists of the glomerulus and Bowman’s 
capsule, and a renal tubule (Figure 1.1 A). Nephron segments are present in both the renal cortex and 
medulla. Nephrons are separated by interstitial space, which contains connective tissue and 
vasculature.  
Renal corpuscles, located exclusively in the cortex, consist of a looped and anastomotic group of 
capillaries called a glomerulus, which is suspended in a globular pouch – the Bowman’s capsule. The 
glomerulus is suspended off a vascular pole consisting of the vascular supply and drainage of the 
glomerulus; the afferent arteriole and efferent arteriole respectively.  
The glomerular capillary consists of fenestrated endothelial cells which are wrapped by tightly 
interdigitating podocytes; these two cell types and their common basement membrane make up the 
filtration barrier (Figure 1.1 B). The glomerular tuft sits on the mesangium, which consists of 
mesangial cells and their secreted ECM.  Plasma is forced through the filtration barrier forming the 
urinary filtrate, leaving the unfiltered plasma, blood cells and proteins behind in the capillaries which 
exit the glomerulus in the efferent arteriole.  
At the opposite side of the Bowman’s capsule to the vascular pole is a drainage point, or the urinary 
pole, which marks the beginning of the renal tubule; a structure which dominates renal tissue. The 
renal tubule, a tube of simple epithelium, changes in cellular structure and function as it progresses 
distally (Figure 1.1 A).  The proximal convoluted tubule (PCT) is the first component of the renal 
tubule. The PCT is mainly cortex bound, though eventually it straighten out and will travel deep to 
become continuous with loop of Henle in the medulla. The loop of Henle progresses deep into the 
medulla and then turns like a hairpin to move up to the cortex where it morphs into the distal tubule. 
The distal tubule rises out of the medulla to lie adjacent to the vascular pole of the nephron’s source 
glomeruli thus forming part of the juxtaglomerular apparatus, before draining into the connecting 
tubule. Connecting tubules drain multiple distal tubules, thus the distal tubule is the last nephron 
specific structure. Collecting ducts collect urine from many collecting tubules.  
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Nephron anatomy displays heterogeneity related to segment length and spatial position of corpuscle 
within the cortex; these however the order of the basic structural units does not vary (Kriz et al., 
1988).   
 
 
Figure 1.1: Schematic of the Nephron, the Glomerular Filtration Barrier and Mesangium 
A is a nephron schematic showing its anatomy and distribution through the kidney. KEY: 1- 
Glomerulus, 2- Proximal convoluted tubule, 3- Proximal straight tubule, 4- Thin descending limb of 
loop of Henle, 5- Thin ascending limb of loop of Henle, 6- Thick ascending limb of loop of Henle, 7- 
Distal tubule component of juxtaglomerular apparatus (Macula Densa), 8- Distal convoluted tubule, 
9- Connecting tubule, 10/11- Collecting duct. Adapted from Kriz et al. (1988) 
B depicts a cross section across single glomerular capillary and respective filtration barrier 
components. Urinary filtrate is the component of plasma which can pass through (arrows) the 
filtration barrier and supporting glycoprotein matrices. ‘Holes’ of the filtration barrier are created by 
gaps between cell membranes; the fenestrations of the endothelium (dashed red line) and 
interdigitating foot processes of the podocytes (blue). Urinary filtrate has to also pass through two 
glycoprotein structures: the endothelial glycocalyx (grey line) and combined endothelial-podocyte 
A B 
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basement membrane (black line). Glomerular capillaries are supported by mesangial matrix (pink) 
containing mesangial cells (peach).  
1.3.2  Nephron Function 
 
The function of the nephron is to selectively filter the plasma, which occurs at the renal corpuscle, and 
reabsorb essential components of the urinary filtrate –the role of the renal tubule. Many filtered 
substances, such as glucose and amino acids are quickly reabsorbed by the proximal tubule; while 
sodium and water, also predominantly reclaimed in the proximal tubule, are reabsorbed by site-
specific transporters and channels throughout the length of the nephron. Connecting tubules and 
collecting ducts also play a role in reabsorption, though a minor one compared to the reabsorptive 
capacity of the nephron. Renal epithelial tubule cells also have a role in excreting unwanted 
metabolites into the urinary filtrate. Urine is the final product of the kidney tubular system and is 
unaltered from the collecting duct onwards. 
1.3.3  Nephron associated vasculature  
 
The kidney has a unique vascular nature: the afferent arteriole receives blood from the systemic 
circulation which feeds into the glomerulus. Unfiltered blood components are then drained by the 
efferent arterioles. The efferent arteriole forms the effective vascular supply of the kidney, with 
peritubular capillaries branching off the efferent arteriole to supply the various tubular components of 
the nephron.  
1.4  Hypertension  
1.4.1  Epidemiology  
 
EBP is a leading risk factor for mortality; it is currently attributed to over an eighth of worldwide 
deaths (Alwan, 2011). EBP, hypertension, raised blood pressure and high blood pressure are 
interchangeably used terms applied by the various global authorities on hypertension when collecting 
epidemiological data. Hypertension or EBP is used to describe the clinical situation of a patient who 
has a raised systolic blood pressure of ≥140mmHg, a diastolic blood pressure of ≥90mmHg or is 
currently being prescribed antihypertensive medications (Alwan, 2011; Mancia et al., 2013; Go et al., 
2014). The World Health Organisation (WHO) estimates that 40% of the global population ≥25 years 
are hypertensive (Alwan, 2011). The American Heart Association has collected data to suggest that 
over a third of adults over 20 in the USA are hypertensive (Go et al., 2014); locally sourced 
epidemiological data places New Zealand’s prevalence at 30.4% for the same age group (McLean et 
al., 2013).  
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1.4.2  Aetiology  
 
The vast majority (90-95%) of hypertension cases are generally attributed to a loosely described 
“unknown cause” and are labelled under the category of essential hypertension (Mulvany, 2012). 
Genome wide association studies have clarified that elevated blood pressure can be the result of gene-
environmental interactions; variations in up to 30 different genes have been associated with 
hypertension (Ehret et al., 2011). Environment interplay is observed in studies looking at migrant 
population groups; migrants tend to assume the same levels of hypertension as the existing population 
of their destination (He et al., 1991; Whelton, 1994). Environmental influence has been further 
confirmed by successful interventional studies; changing the diets of hypertensive patients has shown 
efficacy in reducing blood pressure, a beneficial effect also augmented by the resulting weight loss 
(Sacks et al., 2001; Sacks et al., 2010).  
Though the absolute triggers for the development of essential hypertension are unknown, the simple 
mechanism by which blood pressure is raised has been elucidated. A rise in total peripheral resistance 
(TPR) due to the remodelling of small resistance vessel architecture has been identified as the 
pathophysiological reason for the resulting increase in blood pressure (Mulvany, 2012). The 
remodelling of these small muscular arteries is associated with increased levels of vascular reactive 
oxygen species and low-grade inflammation; both of which are thought to originate due to 
dysfunction of   the renin-angiotensin-aldosterone-system (RAAS) (Montecucco et al., 2011; Rodrigo 
et al., 2011). The pattern of remodelling in essential hypertension is unique, other resistance-based 
hypertensive pathologies follow different patterns; for example patients with isolated systolic 
hypertension are characteristically seen to have elastic artery stiffening through remodelling, with 
little remodelling of muscular arteries (McEniery et al., 2007). 
1.4.3  Pathophysiology of Hypertensive Cardiorenal damage. 
 
Mechanical ‘stretch’ stress placed on the structure of the heart and kidney is the direct driver of 
cardiorenal damage in elevated blood pressure states. The mechanical ‘stretch’ of the left ventricle 
triggers cardiac pathology, whereas the vascular components of the kidney are affected in elevated 
blood pressure (Jaalouk et al., 2009; Schmieder, 2010).  
1.3.3.1  Cardiac Damage  
 
The unremitting effects of a chronic haemodynamic load placed on the heart through uncontrolled 
systemic hypertension can potentially lead to hypertensive heart disease (HHD). As previously 
mentioned, vascular resistance is increased in essential hypertension and as a result the heart must 
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adapt to generate more force to maintain sufficient systemic perfusion.  HHD development can 
therefore be seen as a compensatory response to the systemic resistance (Berk et al., 2007).  
Hypertensive heart disease can provoke varied characteristic changes in the myocardium. 
Cardiomyocytes and fibroblasts detect biomechanical stretch, resulting in the release of growth factors 
into the cardiac tissue (Hunter et al., 1999; Camelliti et al., 2005). These growth factors stimulate the 
synthesis of cardiomyocyte intracellular contractile proteins, resulting in cellular hypertrophy (Jaalouk 
et al., 2009).  This hypertrophic enlargement of myocardial cells results in left ventricular hypertrophy 
(LVH). Two patterns of LVH can occur in essential hypertension: concentric, where only left 
ventricular thickness in increased; and eccentric, wall thickness is increased with an associated 
ventricular ballooning. It was typically thought only concentric hypertrophy developed with HHD, 
however a meta-analysis has shown that eccentric hypertrophy is more common than concentric 
(Drazner, 2011; Cuspidi et al., 2012). Both types of hypertrophy set the heart up for eventual failure if 
HHD progresses, however through different mechanisms (Drazner, 2011). 
As previously explored, the fibroblast maintains the structural integrity of the cardiac ECM. During 
HHD, among other forms of cardiac pathology, unique ECM secreting cells or myofibroblasts form 
from cardiac fibroblasts (Berk et al., 2007). These cells, influenced by the abnormal signalling in the 
myocardial environment, alter the nature and volume of the ECM to potentially produce a 
pathological effect on cardiac function. The ECM components, collagen I & III for example, are no 
longer expressed in optimal ratio or orientation, altering the mechanical and potentially impeding the 
electrical characteristics of the left ventricle (Berk et al., 2007).  
The concentric pattern of HHD is typically associated with unregulated increases in ECM. This 
accumulation causes the myocardium to become stiff and can lead to functional impairment (Ahmed 
et al., 2006). A stiff left ventricular wall can impair relaxation of the myocardium, thus constraining 
ventricular filling during diastole (de Simone et al., 2005; Spinale, 2007). If untreated, this diastolic 
dysfunction may develop into symptomatic heart failure. During eccentric hypertrophy the structure 
of the ECM is thought to weaken (Drazner, 2011), but does not necessarily accumulate; this allows 
the ventricular wall to stretch producing the characteristic ‘ballooning’ of the ventricle (Spinale, 
2007). Over time, the stretched ventricular wall may become ‘decompensated’ meaning it is unable to 
efficiently eject the contents of the ventricle, termed systolic dysfunction (Berenji et al., 2005; 
Drazner, 2011). Therefore progression of eccentric hypertrophy may also lead to heart failure.  
Abnormal accumulation of the ECM, associated with concentric hypertrophy (Spinale, 2007), disrupts 
the electrical signalling of the heart, leading to the generation of potentially fatal arrhythmias. 
Adjacent cardiomyocytes are wedged apart by the increasing extracellular matrix, potentiating 
irregularities in conduction between cardiomyocytes (de Jong et al., 2011). This may result in a 
reduction in conduction velocity within regions of the myocardium; a re-entrant circuit can develop, 
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triggering the initiation of an arrhythmia. These arrhythmias have the potential to lead to a fatal 
contraction dysfunction such as ventricular fibrillation (Zipes et al., 1998). A small ECG study of 
patients with LVH has demonstrated a clear increase in arrhythmogenic activity in patients with LVH 
(McLenachan et al., 1987).  
1.3.3.2  Renal Damage  
 
Hypertensive nephrosclerosis develops over a period of chronic blood pressure elevation. 
Glomerulosclerosis, the expansion of ECM within the glomerular tuft, and tubular atrophy 
characterise the histological changes during blood pressure elevation (Bidani et al., 2004). A unique 
pattern of glomerulosclerosis is seen in hypertensive nephrosclerosis: global glomerulosclerosis, 
where ECM expansion has completely obliterated the glomerular capillary, is scattered amongst the 
cortex with other glomeruli experiencing varying degrees of glomerulosclerosis (Luke, 1999; Bidani 
et al., 2004; Rosario et al., 2006).  
Chronic hypertension has been proposed to trigger a wave of initial nephron loss resulting in the 
remaining nephrons becoming subjected to hyperfiltration; the mechanical stress on the residual 
glomeruli causes nephrons to progressively ‘drop out’ (Luke, 1999). This pathology is believed to 
stem from an initial injury as a result of sustained afferent arteriole constriction, which is an initially 
protective response to limit haemodynamic stress placed on the glomerular tuft during heightened 
blood pressure. Chronic vasoconstriction can lead to glomerular ischaemia (Luke, 1999). Ischaemic 
glomeruli may consequently undergo global glomerulosclerosis, resulting in nephron loss. If nephron 
loss is widespread hyperperfusion of the remaining glomeruli occurs (Bidani et al., 2004). The stress 
upon these glomeruli may trigger glomerulosclerosis; a change which can progressively eliminate the 
glomerular capillary and therefore reduce glomerular perfusion. As glomerular blood drains into the 
efferent arteriole to supply renal tissue, reduced glomerular perfusion perpetuates gradual nephron 
loss to ischaemic damage (Nangaku, 2006; Rosario et al., 2006).  
Podocyte loss and damage has been shown to occur as a consequence of stretch forces imposed by 
haemodynamic stress (Nagata et al., 1992). Renal biopsy studies have confirmed that glomeruli 
contain a reduced podocyte density in hypertensive nephrosclerosis pathology (Wang et al., 2009). 
Podocyte damage has a variety of consequences: it can trigger glomerulosclerosis and abnormal 
protein filtration (Bidani et al., 2004; D D'Agati, 2008); levels of both are increased in hypertensive 
nephrosclerosis. The presence of protein in the urinary filtrate can further exacerbate nephron loss; 
renal tubule cells are damaged by attempted protein resorption, adding to the unfavourable renal 
environment in hypertensive nephrosclerosis (Zoja et al., 2014).   
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Tubule cell injury from the excessive protein filtration and ischaemia creates an inflammatory 
environment; potentiating an interstitial fibrotic response (Medzhitov, 2010) The potential expansion 
of renal interstitial ECM, carried out by recruited myofibroblasts, can further hinder the diffusion of 
nutrients and oxygen to the tubule cells, potentially causing additional ischaemic stress and nephron 
loss (Zeisberg et al., 2015).  
1.4.3.3  Cardiorenal damage  
 
The development of cardiac dysfunction will often trigger the development of renal dysfunction and 
vice versa, a phenomenon called cardiorenal syndrome (Ronco et al., 2008). In the context of essential 
hypertension the organ injury is chronic; therefore the manifestation of cardiorenal syndrome will also 
be insidious. The development of CKD or heart failure secondary to hypertension will result in 
chronic injury to the other organ, creating a reciprocal loop of cause and affect organ pathology (Bock 
et al., 2010).  
The development of chronic heart failure will eventually lead to a persistent underperfusion of the 
kidney with consequential gradual loss of nephron mass. Over the time period of renal injury the 
kidney attempts to maintain renal pressure by stimulation of the RAAS; however this corrective 
RAAS action which eventually provoke on cardiovascular remodelling leading to further deterioration 
in heart function (Ronco et al., 2008). Similarly in a reno-driven pathology, CKD can lead to 
hypertension through a combination of fluid retention and over stimulation of both the RAAS and the 
sympathetic nervous system; both of which also encourage blood-pressure independent cardiac 
pathology (Bock et al., 2010).  It has been found that a renal transplant can even reverse cardiac 
dysfunction (Bock et al., 2010). Patients with chronic renal disease also have strikingly high risk of 
myocardial infarction; contributing to the fact that they also have a 10-fold higher risk of cardiac 
death (Ronco et al., 2008).  
1.4.4  Current Hypertension Management  
 
Hypertension is typically diagnosed by repeated office blood pressure measurements which exceed 
140 mmHg SBP or 90 mmHg DBP; if observed blood pressure is suspected to differ in unprompted 
situations, hypertension may also be diagnosed by automated home blood pressure monitoring or 
ambulatory blood pressure monitoring recordings (Mancia et al., 2013). Lifestyle modifications are 
recommended after a diagnosis of hypertension and should be emphasised throughout the course of 
treatment. These modifications include changing dietary composition to foods described by Sacks et 
al. in the Dietary Approach to Stop Hypertension (DASH) trials, weight control, regular exercise, 
reducing alcohol consumption and smoking cessation (Sacks et al., 2010; Mancia et al., 2013; James 
et al., 2014) If adherence to these lifestyle modifications fails to normalise blood pressure, 
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pharmacological therapy will be considered; however patient age, stage of hypertension, 
cardiovascular disease risk and co-morbidities such as diabetes and chronic kidney disease may 
prompt immediate pharmacological therapy upon diagnosis of hypertension (Mancia et al., 2013). 
Guideline groups are fairly consistent in recommendations on the choice of first line antihypertensive 
therapies. Mono therapy is commenced with thiazide diuretics, calcium channel blockers (CCBs) or 
an angiotensin converting enzyme inhibitor (ACEi) (Mancia et al., 2013; James et al., 2014). 
Depending on the severity of the hypertension and presence of confounding factors, these drugs may 
be applied in combination; in addition an angiotensin receptor blocker (ARB) may be substituted for 
an ACEi if they are not tolerated. The European Society of Hypertension and European Society of 
Cardiology guideline also recommend beta-blockers as first line treatment for uncomplicated 
hypertension; this is despite a Cochrane review revealing their inferiority compared to other first line 
antihypertensive classes (Wiysonge et al., 2007; Mancia et al., 2013). 
Lessening disease burden of hypertension by lowering blood pressure significantly reduces levels of 
associated mortality (Hansson et al., 1998; Lewington et al., 2002; Group et al., 2015). Benefits also 
lie with blocking pathological pathways enhanced by hypertension itself, not only decreasing blood 
pressure. Numerous studies demonstrate that cardiovascular disease morbidity and mortality is 
reduced after the addition of low-dose aspirin or a statins to standard antihypertensive therapy 
(Hansson et al., 1998; Sever et al., 2003; Ridker et al., 2005). 
1.4.5  Rat Models of Hypertension  
 
Rats are the most commonly used animal for hypertension research (Pinto et al., 1998); reflective on 
both the heavy use of rats in all types of pharmacological testing and physiological research and 
abundance of reliable hypertensive rat models. In meeting the requirements associated with these 
studies, animal models of hypertension should be easily reproducible, require minimal intervention 
and should be specifically comparable to human hypertension (Badyal et al., 2003). These 
requirements have pushed development for a variety of hypertensive rat models.    
1.3.5.1 Genetic Models 
 
The most used rat hypertensive model is the spontaneous hypertensive rat (SHR) (Pinto et al., 1998). 
SHRs contain a cocktail of pro-hypertensive genes, acquired through inbreeding rats with elevated 
blood pressure (Lerman et al., 2005). As a result of this genetic predisposition, SHR’s develop 
hypertension at 5-6 weeks of age with no intervention; blood pressure continues to rise until SBP 
stabilisation at around 180-200mmHg (Pinto et al., 1998).  
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Another genetically predisposed hypertensive model is the Dahl salt-sensitive rat; however 
hypertension is inducible in response to a high salt diet exposure.  This phenomenon allows for a 
controlled onset of hypertension.  
1.3.5.2   Chemically and Surgically Induced Models 
 
Chronic infusion of angiotensin II (ANGII) may be used to induce hypertension through the 
hormones’ physiological effects (see  section 1.4.2.1) (Lerman et al., 2005). Oral administration of the 
nitric oxide synthase inhibitor, L-N
G
-Nitroarginine methyl ester (L-NAME), or chronic infusion with 
the mineralocorticoid deoxycorticosterone acetate (DOCA) are also commonly used mechanisms to 
induce systemic hypertension in rats (Dornas et al., 2011). However in order to induce a fast onset of 
hypertension in the DOCA model, a reduction of renal mass, usually via unilateral nephrectomy, or 
administration of a high salt diet must be commenced (Dornas et al., 2011). Aldosterone induced 
hypertension is also achieved in the same ways as DOCA hypertension.  The intensive level of 
intervention needed to achieve aldosterone and DOCA mediated hypertension makes it difficult to 
extrapolate findings from these models to the pathologies seen in clinical hypertension. 
The first surgical model of hypertension was developed in 1934. The Goldblatt method induces 
hypertension by placement of a clip on the renal artery, decreasing kidney perfusion. The resultant 
hypoperfusion of the kidney triggers overstimulation of the RAAS (see section 1.4.2.1) (Pinto et al., 
1998). Other surgical options have included bulk reduction of renal mass through unilateral 
nephrectomy and reduction of the remaining kidney to produce a subtotal (5/6) nephrectomy, 
triggering fluid retention. Reduction in nephron also mass is used to potentiate endocrine 
hypertension, as described above; it can also be used in conjunction with the DOCA, aldosterone and 
ANGII infusion models to accelerate the development of hypertension.  
1.3.5.3 Transgenic models 
 
The most common transgenic model of hypertension is the TGR(mREN2)27. Systematic renin 
expression triggers severe hypertension (>200mmHg) from the 5
th
 week of age in both male and 
female rats; however this widespread expression of renin and the resultant severity of hypertension, 
particularly in the male rat, make it hard to extrapolate findings to human hypertension (Dornas et al., 
2011). 
1.3.5.3.1  Cyp1a1-Ren2 Transgenic Rats 
 
The Cyp1a1-Ren2 rat strain is an inbred transgenic line derived from Fischer 344 rats which have had 
the Cyp1a1-Ren2 transgene incorporated into their genome (Kantachuvesiri et al., 2001). Cyp1a1-
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Ren2 rats develop a dose-dependent level of hypertension with ingestion of aryl hydrocarbons, such 
as indole-3-carbinol (I3C) (Heijnen et al., 2014) thereby providing an inducible model of 
hypertension. For this reason, the Cyp1a1Ren2 transgenic was selected as the appropriate, clinically-
relevant model in which to study the effects of pharmacological intervention. 
The Cyp1a1Ren2 transgene, inserted into the Y-chromosome of the Fischer 344 rat, consists of a rat 
Cyp1a1 promoter fragment fused to the mouse Ren2 gene (Kantachuvesiri et al., 2001). Aryl 
hydrocarbons bind to aryl hydrocarbon receptors, which in turn activate the Cyp1a1 promoter (Figure 
1.2). In the case of the Cyp1a1Ren2 transgenic rats, the Ren2 gene is consequently expressed due to 
fusion with the Cyp1a1 promoter. The Ren2 gene expresses renin, which triggers a RAAS-dependent 
rise in blood pressure (Mitchell et al., 2007). The renin protein derived from the Cyp1a1Ren2 
transgene is predominantly hepatic in origin, unlike the renal origin of renin in normal physiological 
conditions (Kantachuvesiri et al., 2001). As a consequence of the transgene being incorporated into 
the Y-chromosome, only males can develop hypertension upon exposure to dietary I3C.   
 
Figure 1.2: Expression of renin in the Cyp1a1-Ren2 transgenic rat 
Renin synthesis is inducible in the Cyp1a1Ren2 strain as dietary administration of aryl hydrocarbons, 
such as indole-3-carbinol (I3C), activates the aryl hydrocarbon receptor which in turn binds to the 
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1.5  Mineralocorticoid Receptors  
 
Mineralocorticoid receptors are the putative receptors of the mineralocorticoid hormone aldosterone. 
Aldosterone was first isolated in 1954, for the greater portion of the past 62 years aldosterone was 
thought to simply play a physiological role by increasing blood pressure through salt retention (Fiore 
et al., 2006). Not until the 1990’s did the MRs role as a pathological modulator gather significant 
scientific interest; in 1999 the MR antagonist, spironolactone, was shown in the RALES trial to 
improve outcomes in heart failure patients with a reduced ejection fraction, enlightening the wider 
medical community to the pathological characteristic of  MRs (Pitt et al., 1999).  
The following section will explore the characteristics of the mineralocorticoid receptor, aldosterone, 
the physiological and pathological roles of MRs before discussing the pharmacological effects of 
MRAs, with spironolactone as a focus.  
1.5.1  Mineralocorticoid Receptor Characteristics 
 
Mineralocorticoid receptors belong to the nuclear receptor family; they reside in the cell cytosol 
bound to a multi-protein complex. Dissociation from this complex occurs upon agonist binding to the 
MR (Huyet et al., 2012). The activated MRs translocate to the nucleus to facilitate protein synthesis; 
in addition MRs can also trigger non-genomic pathways by co-activating other receptors, such as the 
epidermal growth factor receptor, for rapid signalling (Montezano et al., 2008; Dooley et al., 2012). 
MR signalling depends on the stability of the MR-ligand complex formed upon activation, rather than 
the affinity the ligand may have for the receptor (Hellal-Levy et al., 1999; Huyet et al., 2012). 
Cellular oxidative stress, commonly present under RAAS upregulation, stabilises the MR-ligand 
complex enhancing MR signalling (Shibata et al., 2011) (Shibata et al., 2008) (Nagase et al., 2012). 
Cortisol and aldosterone have equal affinity for MRs; however MR selectivity is generally conferred 
to aldosterone due to the instability of the cortisol-MR complex, (Hellal-Levy et al., 1999; Funder, 
2010; Huyet et al., 2012). Therefore rather than activating the MR, cortisol acts as a competitive 
antagonist unless cortisol levels are excessively elevated. Inhibition of 11beta-hydoxysteroid 
dehydrogenase type 2, an enzyme which breaks down cortisol to an inactive cortisone, allows 
successful cortisol MR activation in renal tubular cells; however the mechanism is not through a 
build-up of cortisol, rather the change of the cellular oxidative status (Funder et al., 1996; Funder, 
2010). Extreme oxidative stress has been shown to trigger pathological cortisol activation of MRs, 
however it has only been documented in a cardiac ischaemia-reperfusion model (Mihailidou et al., 
2009).  
 




1.5.2  Aldosterone  
 
Aldosterone, a steroid hormone of the mineralocorticoid family, is synthesised primarily in zona 
glomerulosa of the adrenal cortex. Elevated potassium, the presence of ANGII and acutely elevated 
adrenocorticotrophic (ACTH) trigger aldosterone synthesis (Marney et al., 2007). Aldosterone release 
occurs immediately upon synthesis, venous drainage of the adrenal cortex then distributes aldosterone 
systemically.  
Aldosterone is not typically thought of as a hormone which acts alone; rather it is part of the renin-
angiotensin-aldosterone system (RAAS), described in more detail below.  
1.5.2.1  Renin-Angiotensin-Aldosterone System  
 
The RAAS is a physiological mediator of blood pressure. It is an endocrine based system controlled 
by a negative feedback loop. The primary effector hormone is ANGII which carries out the majority 
of the physiological effects.  
Renin, released by renal juxtaglomerular cell, triggers the RAAS cascade in response to a variety of 
stimuli which are outlined in Figure 1.3. The protease action of renin cleaves angiotensinogen to 
create angiotensin I; angiotensin converting enzyme (ACE), present primarily in vascular endothelium 
amongst other tissues, then converts newly formed angiotensin I to ANGII. ANGII in turn acts upon 
the angiotensin receptor subtypes.  The angiotensin subtype 1 receptor (AT1R) is considered to 
mediate the major blood pressure regulating effects of ANGII through direct vasoconstriction, 
sympathetic nervous system regulation, increased sodium resorption and aldosterone release. The 
resulting increase in blood pressure, and ANGII levels, negatively feedback to reduce renin secretion 
in a physiologically controlled individual (Padia et al., 2013).  
AT1R receptor activation also promotes pathological cellular activity and inflammatory pathway 
activation in cardiac and renal tissue (Atlas, 2007). Inflammation may exacerbate pathological 
responses underway in the heart or kidney, leading to AT1R assisted tissue damage. Conversely, the 
AT2R receptor subtype, also activated by ANGII, has been shown to antagonises AT1R pathological 
effects in a plethora of animal studies and in vitro studies (Jones et al., 2008); however this supposed 
beneficial effect is yet to be demonstrated in humans (Hall et al., 2007; van Vark et al., 2012; Ferrari 
et al., 2013). 




Figure 1.3: Physiological aspect of the RAAS 
Juxtaglomerular cells (JGCs), specialised smooth muscle cells of the renal afferent arterioles, secrete 
renin in response to a variety of blood pressure-dependant inputs. A fall in blood pressure is detected 
and relayed to JGCs via several mechanisms: baroreceptors increase sympathetic outflow to JGCs due 
to a reduction in stretch, macula densa cells of the distal tubule increase paracrine signalling in 
response to a reduction in sodium filtration, and JGCs themselves directly sense a reduction in the 
stretch of renal afferent arterioles. Renin instigates a cascade ending in ANGII formation which 
mediates a rise in blood pressure, either through direct mechanisms or through aldosterone release 
 
1.5.2.2  Aldosterone breakthrough 
RAAS inhibitors such as ACEi and ARBs, briefly mentioned in section 1.4.4, target the RAAS to 
lower blood pressure. ACEi’s, which inhibit ACE, prevent the formation of ACE-dependent ANGII 
whereas ARBs antagonise AT1R; both of these drug classes should theoretically supress aldosterone 
plasma concentration. However a phenomenon called “aldosterone breakthrough”, where aldosterone 
plasma levels are unexpectedly elevated or normal following RAAS blocker intervention, has been 
observed in hypertensive and heart failure patients treated with ARBs or ACEi’s (Jorde et al., 2002; 
Bomback et al., 2007). The mechanism of aldosterone breakthrough is unknown, though it likely 
includes the ANGII-independent pathways of aldosterone synthesis (mentioned in section 1.4.1). 
Therefore the proposal that the effects of aldosterone are entirely supressed with ACEi or ARB use is 
unfounded.  
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1.5.3  Physiological Role of Mineralocorticoid Receptors  
 
Aldosterone acts on renal MRs to facilitate sodium resorption; more specifically upon MRs of 
epithelial cells of the distal tubule and connecting tubule (Meneton et al., 2004). The collecting duct 
also has a role in MR sodium resorption, although minimal relative to the prior components of the 
renal tubule. Post MR activation there is a rapid transcription and increase in the cell surface 
expression of two transporter proteins (Loffing et al., 2001; Summa et al., 2001): eNaC, an epithelial 





ATPase pump to the basal-lateral surface of the epithelial cell (see Figure 1.4 for orientation). 





ATPase proteins (Lee et al., 2008; Thomas et al., 2008). Further to changes in activity and cell 
surface expression, aldosterone also increases protein synthesis of both of these transporters (Lee et 
al., 2008). These cellular changes increase sodium reabsorption from within the renal tubule, shifting 




 ATPase ion 
transporter powers this sodium transport. Salt reabsorption drives water resorption; therefore this 
water also shifts out of the tubule.  
Potassium secretion is interdependent with sodium reabsorption; the influx of sodium into the cell 
electrochemically pushes out potassium through ion specific channels (Arroyo et al., 2011). 
Depending on potassium status, MR-related potassium excretion can be modulated to minimise 
extremities in plasma concentration; in addition MR activation in the distal tubule increases the action 
of a potassium-proton pump, promoting a reduction in potassium loss (Arroyo et al., 2011; Ingelfinger 
et al., 2015). 
Overall the physiological role of MR activation is to increase sodium reabsorption, increasing fluid 
retention. In the wider role as a mediator of the RAAS, MRs serve to increase/prevents a drop in 
blood pressure. 
 





Figure 1.4: Classical Action of Aldosterone in the Aldosterone Sensitive Cells of the Renal tubule.  
The apical surface of the cell faces the lumen of the renal tubule whereas the basal side faces the renal 
interstitium. Aldosterone binds to cytoplasmic MRs which translocate to the nucleus to regulate gene 
expression. The quickly expressed upregulating signalling proteins increase the activity (thin arrows) 




 ATPase ion 




 ATPase protein expression (bold 
arrows) are also instigated by MR activation. This change in cell characteristics encourages potassium 
excretion and sodium resorption, a shift which will increase water retention. 
 
1.5.4  Pathological Role of mineralocorticoid receptors   
1.5.4.1  Cardiac 
 
Landmark clinical trials focussing on heart failure patients established the role of MRAs as having 
therapeutic benefits through anti-fibrotic effects, these trials used both spironolactone and eplerenone 
as the MRA of interest. Pitt et al. demonstrated that a reduction in mortality in patients with severe 
heart failure is reduced with the addition of an MRA to standard therapy (Pitt et al., 1999; Pitt et al., 
2003b); heart failure progression is characterised by increased fibrosis, as is hypertensive heart 
disease. Sudden cardiac death, often arrhythmia related, was significantly reduced in both trials (Pitt 
   
19 
 
et al., 1999; Pitt et al., 2003b); also linked to excessive cardiac ECM (Zipes et al., 1998). Further 
evidence for the anti-fibrotic effect of spironolactone came from post-hoc analysis of one of these 
trials; only patients with a serum biomarker of ongoing fibrosis, aminoterminal peptide of type III 
procollagen (PIIINP), benefitted from spironolactone therapy (Zannad et al., 2000). A recent trial 
from Pitt et al. has shown that the indication for MRAs for heart failure is limited only to those with a 
reduced ejection fraction; amongst heart failure patients with compromised diastolic function there is 
no benefit of adding spironolactone to standard therapy (Pitt et al., 2014). 
A reduction in cardiac fibrosis has been demonstrated with MRA therapy in a variety of hypertensive 
rodent models (Brilla et al., 1993; Lal et al., 2003; Mandarim-de-Lacerda et al., 2003; Azibani et al., 
2012; Luther et al., 2012); although one study conducted in elderly SHR rats has shown no reduction 
(Kambara et al., 2003). In humans a small clinical study of patients with essential hypertension and 
left ventricular hypertrophy, consistent with early stage HHD, demonstrated that spironolactone 
addition to ACEi therapy reduced serum PIIINP levels; suggesting a MRA linked reduction in 
ongoing fibrosis (Sato et al., 2002). Reversal of left ventricular hypertrophy has been demonstrated 
clinically with addition of an MRA to ACEi therapy (Sato et al., 1999; Sato et al., 2002; Pitt et al., 
2003a). Modelling within animal studies have shown that spironolactone prevents LVH in 
hypertensive rats; however the beneficial effects in terms of LVH were typically accompanied though 
not exclusively by a drop in blood pressure (Lal et al., 2003; Luther et al., 2012). The value of MRA 
antagonists in LVH is further borne out by in vitro studies which suggest that MR activation is 
implicated in cardiomyocyte hypertrophy (Pankey et al., 2012).  
A series of studies by Rickard et al., have demonstrated the specific involvement of MR signalling in 
macrophages, cardiomyocytes and endothelium in the development of inflammatory cardiac fibrosis. 
Deletion of cell-specific MRs in macrophages, cardiomyocytes and endothelium reduced cardiac 
fibrosis (Rickard et al., 2009; Rickard et al., 2012; Rickard et al., 2014). Deletions of MRs in 
cardiomyocytes and endothelium prevented macrophage infiltration, whereas MR deletions in 
macrophages and cardiomyocytes reduced levels of pro-fibrotic paracrine signalling – including TGF-
β1 signalling. These studies demonstrate the omnipotent nature of the MR activation, and clearly 
indicate that MR antagonism may act on multiple cellular levels to prevent cardiac fibrosis in HHD. 
1.5.4.2  Renal 
 
Clinical, animal and in vitro studies have provided evidence that proteinuria and podocyte damage are 
reduced by administration of MRAs; proteinuria, as discussed earlier, is often a manifestation of 
podocyte damage. Randomised control trials (RCTs) exploring monotherapy options for essential and 
isolated systolic hypertension have found the MRA eplerenone is superior at reducing 
microalbuminuria compared to ACEi and CCB therapy, while providing a similar antihypertensive 
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effect (White et al., 2003; Williams et al., 2004). A recent meta-analysis of CKD patients has 
established than proteinuria is reduced following addition of MRA therapy onto to standard therapy 
(ACEi or ARB use) (Bolignano et al., 2014). Animal studies exploring the effects of numerous types 
of induced hypertension have demonstrated that proteinuria and podocyte damage are abrogated by 
use of a MRA (Nagase et al., 2006; Nagase et al., 2007; Ortiz et al., 2007; Shibata et al., 2008; Ikeda 
et al., 2009). Kidney biopsies from CKD patients confirm that patients with severe albuminuria had 
increased levels of SgK1 among other MR signalling proteins compared to CKD patients without 
albuminuria (Quinkler et al., 2005); adding non-pharmacological evidence for the human proteinuria-
MR link.  
Podocyte damage seems to be triggered though MR triggered oxidative stress. Animal hypertensive 
studies have shown use of a potent antioxidants reduce proteinuria and podocyte damage to the same 
degree as MRA therapy; suggesting that MR-triggered oxidative stress is the root cause of podocyte 
dysfunction (Nagase et al., 2007; Shibata et al., 2007; Yuan et al., 2012). In vivo studies of podocytes 
have confirmed MR activation leads to the instigation of oxidative stress (Zhu et al., 2011; Yuan et 
al., 2012). In humans Renke et al. have demonstrated a decrease in a urinary marker of oxidative 
stress after administration of spironolactone (Renke et al., 2008). 
As described podocyte damage or loss promotes ‘fibrosis’ of the glomerulus or glomerulosclerosis, an 
effect which seems to be prevented with MRA therapy. Glomerulosclerosis was reduced in rodent 
hypertensive models treated with MRA, these findings were associated with reduced podocyte injury 
(Nagase et al., 2006; Ikeda et al., 2009). Mesangial cells have also been indicated in MR-facilitated 
pathology. Pro-fibrotic signalling by mesangial cells in vivo has been demonstrated to be enhanced by 
MR activation in a rodent hypertension model; in vitro studies have confirmed this is a mesangial-MR 
specific response (Terada et al., 2008). 
1.5.5  Mineralocorticoid receptor antagonists 
 
MRA’s have been in clinical use for well over 50 years. Spironolactone was invented in 1959, and 
within the next year it was be used clinically (Garthwaite et al., 2004). Spironolactone was the only 
drug in the MRA class for nearly 30 years until the invention of eplerenone, a selective MRA in 1987; 
however the era of brisk drug approval for clinical use, which spironolactone had benefited from, was 
over (Garthwaite et al., 2004). Eplerenone was approved for clinical use in 2002, lagging behind 
spironolactone’s entrance by 40 years.  
In humans spironolactone has a short half-life (1.4hr) due to rapid metabolism by hepatic esterase 
enzymes; however its metabolites are pharmacologically active, as well as spironolactone itself. The 
dominant metabolites 7α-thiomethylspirolactone and canrenone have far longer half-lives (13.8hr and 
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16.5hr respectively) and hence are responsible for the bulk of the MR antagonism (Overdiek et al., 
1985; Gardiner et al., 1989). Spironolactone pharmokinetics appear to be similar in rats (Kaukonen et 
al., 1998). Spironolactone, spironolactone’s metabolites (SMs) and eplerenone are steroidal MRAs 
(Figure 1.5); they bind in the ligand binding pocket of the MR, preventing the activation of the 
receptor (Yang et al., 2012). 
Spironolactone (and SMs) can also bind to other steroid receptors, notably androgen and progesterone 
receptors; this cross-reactivity is a double edged sword. Antagonism of the androgen receptors leads 
to poorly tolerated side effects in men such as impotence, libido reduction and gynecomastia; however 
in women spironolactone’s androgen blocking effects are utilised to treat hirsutism and acne (Brown 
et al., 2009; Guichard et al., 2013). Eplerenone has limited receptor cross-reactivity thus has a much 
lower incidence of sexual side effects, leading to eplerenone to be well  tolerated compared to 
spironolactone (Struthers et al., 2008).  
 
Figure 1.5: Chemical Structures of Spironolactone, Spironolactone's Metabolites and Testosterone 
When administered, spironolactone (A) is quickly metabolised to create two major products: 7α-
thiomethylspironolactone (B) and canrenone (C).  Both these biologically active metabolites have 
much longer half-lives and carry out the bulk of the MR antagonism. Spironolactone and its 
metabolites are structurally similar to androgens, such as testosterone (D); these similarities are the 
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reason for the steroid receptor cross-reactivity experienced with spironolactone therapy. Adapted from 
Overdiek et al. (1985) and Gao et al. (2005)  
 
MRA’s are best known for blocking the action of aldosterone at the distal and connecting tubule; 
leading to mild diuresis and a reduction in fluid retention. The diuretic properties indicate the use of 
spironolactone in a range of oedematous conditions and hypertension. MRA use has been shown to be 
particularly effective in resistant hypertension, hypertension which persists despite combination of 
first-line antihypertensives (Williams et al., 2015). Primary aldosteronism is also effectively treated 
with spironolactone. Blocking MR mediated excretion of potassium has also resulted in 
spironolactone use for hypokalaemia. Only in the last 20 years have studies focussed on the potential 
benefits of spironolactone beyond reducing fluid retention; identifying diuretic-independent 
cardioprotective properties in patients with severe heart failure, creating new clinical indications for 
its  use (Pitt et al., 1999) (Pitt et al., 2003b).  
1.6  Study Rationale 
 
Elevated blood pressure is a well-established mediator of cardiorenal and vascular damage. Use of a 
MRA reduces blood pressure through the inhibition of the classical MR-response; however clinical 
trials have confirmed protective benefits of blocking MR activation beyond reduction in blood 
pressure in chronic renal and cardiac disease (Pitt et al., 1999; Pitt et al., 2003b; Bianchi et al., 2006).  
Comparing the protective benefit of a drop in blood pressure in a MR-independent fashion to the use 
of a MRA may help isolate the protective benefits of MR antagonism beyond a fall in blood pressure.  
This study also aims to be relevant to the treatment of hypertension in humans. Hypertension is not 
diagnosed and treated upon development; rather it is typically diagnosed by screening by a primary 
health professional. Therefore it would be pertinent for a hypertensive animal study to have a period 
of untreated established hypertension before pharmacological intervention.  
The study uses the Cyp1a1-Ren2 transgenic rat as a hypertensive model; the rats were given, 
spironolactone, amlodipine or no pharmacological intervention after a period of induced hypertension. 
Amlodipine, a dihydropyridine CCB, was used to instigate a direct antihypertensive effect. 
Comparing the protective effects of amlodipine and spironolactone in a chronic hypertensive state 
would allow the investigation of the benefits of MR antagonism independent of a drop in blood 
pressure; assuming a similar antihypertensive effect  between the two interventions.  
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1.7  Aim and Hypotheses   
 
The aim of the experiments detailed in this thesis is to explore the potentially beneficial impact of 
blocking MR activation in the kidney and heart in the transgenic Cyp1a1Ren2 hypertensive rat; 
beyond the antihypertensive effect of MR antagonism.  
The first hypothesis of these experiments is that spironolactone and amlodipine will reduce the 
fibrotic, pro-inflammatory and structural impact of the induced hypertensive state in the Cyp1a1 
transgenic rats. The second hypothesis is that spironolactone will show superiority over amlodipine in 
reducing the impact of hypertension.  
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Chapter 2:     Methods 
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2.1  Materials and Reagents 
 
All reagents were purchased from Sigma-Aldrich (Auckland, New Zealand) or BDH (Palmerston 
North, New Zealand) unless otherwise stipulated. Standard rat chow (irradiated rat and mouse diet) 
was obtained from Specialty Feeds (Glen Forrest, Australia). The I3C was obtained in powdered form 
(Chem-Impex International Inc, Wood Dale, USA) and was shipped to Specialty Feeds for 
incorporation into rat chow. 
2.2  Animals 
 
24 male Cyp1a1-Ren2 transgenic rats were obtained from the University of Otago Animal Resource 
Unit (Dunedin, New Zealand) at 4 – 6 weeks of age. The transgenic rats were stored in a Physical 
Containment Level 2 (PC2) room; complying with the Biosecurity Act 1993 and the Hazardous 
Substances and New Organisms Act 1996. The PC2 room had a 12 hour day-cycle and was kept at a 
constant humidity and temperature. Drinking water (Dunedin tap water) and rat chow were available 
ab libitum for the duration of the study. Standard rat chow was administered on arrival at the Hercus 
PC2 facility until eight weeks of age. Approval from the University of Otago Animal Ethics 
Committee was obtained for all experimental procedures conducted during this study (Animal Ethics 
Committee #: 51/13). All procedures described were carried out in strict accordance with the 
‘Guidelines on the Care and Use of Laboratory Animals’ set out by the University of Otago Animal 
Ethics Committee. Rats were cage housed in pairs for the duration of the experiment.  
2.2.1 Selection of Hypertensive Diet 
 
Pilot experiments conducted by another student member within the research group confirmed that 
exposure of different concentrations (0.125 – 0.25% w/w) of the I3C diet elevated systolic blood 
pressures consistently and in a dose-dependent manner (personal communication, Catherine Leader). 
Dosing the animals with 0.167% w/w I3C diet for 2 weeks produced an elevated mean systolic blood 
pressure of 176.5mmHg with no significant deleterious effects on animal condition. Elimination of the 
I3C from the diet resulted in systolic blood pressures returning to normal ranges within 4 days. This 
pilot data led to the adoption of a 0.167% w/w dose of I3C as the hypertensive trigger. The 0.167% 
w/w I3C containing rat chow was prepared commercially (Specialty Feeds, Glen Forrest, Australia) 
for the project. 
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2.2.2  Experimental Protocol 
 
Regular animal handling began initially at 7 weeks of age to allow acclimation of the animals in 
preparation for blood pressure monitoring. At 8 weeks of age animals were initially randomised to a 
hypertensive group (rat chow containing 0.167% w/w dose of I3C) or a normotensive group (standard 
rat chow). Due to concerns about the level of stress experienced in the animals, handling and blood 
pressure measurements were discontinued within 2 – 3 weeks for all groups and the I3C diet 
withdrawn from the hypertensive animals. A change of animal handler occurred at this age point and 
this group member continued the animal handling section of the project. Due to the resource 
limitations of the lab, both of experienced animal handlers and animal housing, the amount of rats 
available for this study reduced from 36 to 24. 
The study was recommenced at 19 weeks of age for all rats and the I3C diet re-initiated in the 
hypertensive animal group until termination, as it was intended for the rats at 8 weeks. At 21 weeks – 
experimental day 0, two weeks post initiation of I3C diet for the hypertensive groups, pre-treatment 
systolic blood pressure measurements were obtained in both normotensive and hypertensive groups in 
order to confirm the hypertensive status. The normotensive and hypertensive groups were then 
subdivided into three experimental drug treatment groups as described in Table 1, with n = 4 rats per 
group. Once daily oral dosing of spironolactone (8.82mg/kg), amlodipine (0.44mg/kg) and vehicle 
control commenced on experimental day 40 (40 days post pre-treatment blood pressure 
measurements); dosing continued for the duration of the study. On experimental day 84 a metabolic 
cage stay allowed urine collection. Blood pressure measurements and echocardiogram studies were 
performed on experimental day 85, prior to the termination of the experimental subjects. Figure 2.1 
details the basic outline of the study.   
  Experimental Treatment group 
    Diet Vehicle 
Control 
Spironolactone  Amlodipine  
 Normotensive Group 
(Standard Chow) 
4 4 4 
Hypertensive Group  
(I3C chow) 
4 4 4 
 
Table 1: Description of Experimental Groups 
 




Figure 2.1: Study Timeline 
 
2.2.3  Treatment administration 
 
From day 40, oral doses of 8.82mg/kg of spironolactone (Sigma Aldrich, Auckland, New Zealand), 
0.44mg/kg of amlodipine (Apotex NZ Ltd, North Shore, New Zealand) or vehicle control were 
administered daily via syringe feeding. A 0.4-0.5ml of banana flavoured baby custard (Wattie’s, 
Hastings, New Zealand) was administered to each rat as a delivery vehicle; with the dose of drug 
mixed within the custard. Doses for rats were calculated from human equivalent doses using a Food 
and Drug Administration (FDA) approved allometric scaling equation, seen in Figure 2.1 (Reagan-
Shaw et al., 2008). Human doses chosen for conversion were 100mg/day of spironolactone and 
5mg/day of amlodipine; humans were assumed to weigh 70kg for calculations. The human doses 
chosen were the recommended doses for treatment of essential hypertension from drug specific data 
sheets provided by Medsafe (Medsafe, 2016). 
 
Doses are calculated as mg/kg; when calculating spironolactone dosing the human dose was 100mg, 
assumption of a 70kg person was made, leading to a human dose of 1.42mg/kg. The Km values are 
normalised ratios for weight to body surface area for each species, a surrogate measure for metabolic 
rate; humans have a 6-fold higher Km then rats, thus are assumed to have a slower metabolism by the 
same factor (Reagan-Shaw et al., 2008).  
 
2.3  Physiological Data Collection 
 
Figure 2.2: Allometric Scaling Equation 
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2.3.1  Animal monitoring  
 
The rats on standard chow were weighed weekly, whereas concern for weight condition led to rats on 
the I3C diet to be weighed twice weekly. Rats assigned to the I3C diet were supplemented weekly 
with standard chow due to these weight concerns. 
2.3.2  Urine Collection  
 
On experimental day 84, the animals were maintained in individual rat metabolic cages (Techniplast, 
Louviers, France) over a 9.5 to 12 hour period. Rats were allowed to feed and drink ad libitum during 
this time period. Urine produced during this time period was gravity collected under liquid paraffin in 
a recess in the bottom of the cage in order to minimise loss through evaporation. Before urine volume 
was measured, the collected urine was centrifuged at 1000 relative centrifugal force (rcf) for 1 minute.  
1ml of urine was then removed and stored at -80°C for urinary protein analysis (2.1.3). The remaining 
urine volume was then measured and then converted into a urine production rate over a 12 hour 
period; this standardisation to allowed for different lengths of stay in the metabolic cage.  




Protein Assay kit (Bio-Rad Laboratories Inc., Hercules, USA) was used to quantify the protein 
concentration of urine samples; the kit allows spectrophotometric protein determination through a 
modified Lowry method (Lowry et al., 1951). When defrosted, the urine aliquots were vortexed and 
aliquots were removed to create a series of dilutions for analysis. Bovine serum albumin (BSA) 
standards were also prepared in distilled water to varying concentrations (0, 0.2, 0.4, 0.8, 1.2 and 1.6 
mg/ml). A 96 well microplate (Becton Dickinson, USA) was prepared with 5µL of each BSA solution 
and 1:20 urine dilutions pipetted into each well in triplicate. 25μL of the kit reagent A (alkaline 
copper tartrate solution) was then added to each well of the microplate. After the addition of reagent B 
(dilute Folin reagent, 100 μL/well), the microplate was agitated and left to sit at room temperature for 
20 minutes. Maximum absorbance was measured at λ=750 nm using a Benchmark Plus microplate 
spectrophotometer (Bio-Rad Laboratories Inc., Hercules, USA). The protein concentration of each 
sample was then calculated using the protein standard curve generated on the instrument dedicated 
Microplate Manager v.5.2.1 software package (Bio-Rad Laboratories Inc., Hercules, USA) and 
corrected for the dilution factor used. The resultant urine protein concentrations were then multiplied 
by the urine production rate for the corresponding animal and expressed as the total urinary protein 
excretion over a 12-hour period (mg protein/12hr).  
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2.3.4  Blood pressure monitoring  
 
Blood pressure monitoring was performed under midazolam (Roche Products Ltd, Auckland, New 
Zealand) sedation (1.5mg/kg, intraperitoneal injection) at day 0 and day 85, prior to echocardiography 
analysis. Limited animal handler availability prevented more serial blood pressure monitoring. 
A non-invasive tail pressure cuff and transducer were connected to a non-invasive blood pressure 
controller (ADInstruments, Dunedin, New Zealand) which allowed measurements of systolic blood 
pressure (SBP). Multiple measurements were analysed and recorded on LabChart v.6 software 
(ADInstruments, Dunedin, New Zealand); all clear SBP readings from each rat were taken and 
averaged for analysis. Rats were monitored for variable amounts of time in each session, times were 
determined by the handler’s decision whether enough credible blood pressure measurements were 
made. 
2.3.5  Echocardiography  
 
Echocardiograms were executed using a Vivid E9 cardiac ultrasound machine (GE Healthcare, 
Amersham, United Kingdom) under isoflurane-induced anaesthesia. The echocardiograms were 
performed immediately prior to termination on day 85. The thorax was shaved with clippers, then 
remaining hairs were removed with razor blade to maximise skin contact with the echocardiogram 
probe. The exam primarily collected videos and images observing the long axis view of the heart; 
allowing M-mode imaging to be utilised for analysis. Analysis of left ventricular function was carried 
out using Vivid E9 machine’s software. Ventricular measurements using M-mode imaging were 
performed; this allowed ventricular wall thickness (VWT) measurement at both systole and diastole, 
as outlined in the M-mode image in Figure 2.2. Ten measurements of the intraventricular septal wall 
(IVSW) and left ventricular posterior wall (LVPW) dimensions, at both systole and diastole, were 
performed with M-mode imaging. These readings were subsequently averaged for each ventricular 
wall for both systole and diastole measurements. The systolic and diastolic values were then averaged 
to give a final measurement of each ventricular wall. M-mode imaging also allowed left ventricular 
ejection fraction (LVEF) estimation. 
 




Figure 2.3: Representative M-mode recording used for Echocardiographic analysis 
The M-mode image (left) displays the left ventricular walls at different time points in the cardiac 
cycle. Label A denotes an arrow spanning across the left ventricle posterior wall at diastole, whereas 
B denotes the same wall in systole. C denotes the intraventricular septal wall during diastole, D is the 
same structure in systole.  
A histological section (right) stained with picrosirius red, counterstained with fast green, is shown 
next to the M-mode image to orientate the reader to the cardiac dimensions measured: Label 1 is the 
left ventricular posterior wall; 2 is the intraventricular septal wall. 
 
2.4  Histology and Immunohistochemistry 
 
2.4.1  Termination and tissue collection  
 
Termination of experimental animals was carried out on day 85 under anaesthesia using a halothane-
induced inhalation overdose, immediately following the echocardiography measurements. Following 
laparotomy and removal of the left kidney into ice cold Hartmann’s saline, a midline thoracotomy was 
performed and the heart excised and immediately transferred to ice cold 15mmol/L KCl in 
Hartmann’s solution to arrest the heart. The heart was subsequently flushed by pushing the KCl 
solution through the aorta using a syringe. Post-flushing, the supraventricular tissue was removed and 
remaining ventricles were placed in ice cold 10% neutral buffer formalin (NBF; LabServ, Thermo 
Fisher, New Zealand). 2 hours later the heart was removed and sectioned every 3mm from the apex 
using a rat heart sectioning matrix (Ted Palla Inc., Redding, CA, USA); the first three sections from 
the apex were placed within a histological cassette and stored at 4°C in 10% NBF. After 24 hours in 
10% NBF, the heart sections were placed in 70% ethanol until histological processing. 
The left kidney was quickly transferred to 10% NBF from Hartmann’s solution and remained whilst 
the heart was dissected. After heart dissection the kidneys were taken out of 10% NBF to remove any 
2 
1 
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adherent tissue and to remove the poles of the kidney, placed in a cassette and then quickly returned to 
the NBF solution. The remaining kidney was transferred to 70% ethanol after 24 hours in 10% NBF. 
2.4.2  Tissue processing 
 
Tissue stored in 70% ethanol was embedded and mounted by the University of Otago Histology Unit 
Hercus (University of Otago, Dunedin, New Zealand). Using an Excelsior ES tissue processor 
(Thermo Scientific, USA), the tissue sections were dehydrated in graded increases of ethanol 
concentration (70-100%), soaked in xylene and then block embedded in paraffin wax. The three 
sections of each heart were co-embedded in a single paraffin wax block at the same level and 
orientation so as to appear in the same plane when sectioned. The blocks were then cooled, trimmed 
and sectioned into 4µm slices.  The sections were placed on a 40°C water bath surface and then 
placed on standard glass or Dako Flex IHC slides (Dako, Glostrup, Denmark); depending on eventual 
use. The slides were then baked for one hour at 60°C.  
2.4.3  Histology  
 
Tissue sections from both cardiac and renal tissues were stained with haematoxylin and eosin (H&E) 
to assess structural changes. Picrosirius red staining, which colours collagen I and III fibres bright red, 
allowed assessment of fibrotic change in both renal and cardiac sections; these tissue sections were 
counterstained with fast green. Periodic acid Schiff reaction (PAS) staining of renal tissue was also 
performed to observe levels of glomerulosclerosis. Standard glass slides were used for histology. 
2.4.3.1  Haematoxylin and Eosin  
 
Slides were incubated in two xylene baths for 3 minutes each followed by 100% alcohol for 4 
minutes. The tissue was rehydrated by being moved into 95%, then 70% ethanol for 2 minutes each 
before being placed in running tap water for 1 minute. Slides were stained in Gill’s No. II 
haematoxylin for 4 minutes, then transferred back into running tap water for a further 2 minutes and 
in Scott’s tap water for 2 minutes. Slides were counterstained with eosin for 30 seconds, rapidly 
transferred to running tap water for 1 minute then two 100% ethanol baths for 45 seconds each. Slides 
were placed through two xylene baths for 2 minutes each, with agitation of the slides every minute. 
The slides are then removed from xylene and glass coverslips were mounted using a distyrene 
plasticizer xylene mix (DPX).  
2.4.3.1  Picrosirius red  
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Slides were first dewaxed in xylene for 10 minutes then placed in 100% ethanol for 3 minutes. The 
tissue was then rehydrated by moving the slides through a series of ethanol washes of descending 
concentrations (95%, 85% and 50%) for 1 minute each before being placed in water for 3 minutes.  
Slides were then incubated in 0.1% picrosirius red for 60 minutes, rinsed in water and then placed 0.1 
mol/L HCl for two minutes. Slides were then rinsed in water. Slides were counterstained with fast 
green for 45 seconds, then immediately transferred to 50% ethanol for 1 minute. The sections were 
then dehydrated in ethanol solutions with ascending concentrations; 85% and 95% for 1 minute each 
and 100% ethanol for 3 minutes. The sections were cleared in xylene for 30 seconds, then 
coverslipped using DPX as a mountant. 
2.4.3.1  Periodic acid Schiff staining 
 
Slides were placed in xylene for 10 minutes then rehydrated through a series of ethanol washes of 
descending concentrations (100%, 95%, 85%, 50%) for 4 minutes each; before being placed in double 
distilled water (ddH₂O) for a further 4 minutes. Slides were removed from the ddH₂O and a well, 
drawn on the slide around the tissue section using a Dako pen (Dako, Glostrup, Denmark), the tissue 
well was subsequently filled and left to incubate with 1% periodic acid for 15 minutes. Periodic acid 
was then tapped off the slides and the tissue was briefly rinsed in both tap water then ddH₂O before 
incubation in Schiff’s reagent for 15 minutes. Schiff’s reagent was then tapped off the slides and the 
tissue was dipped in ddH₂O, and slides placed in running tap water for 10 minutes. Sections were 
stained in Gill’s No.2 haematoxylin for 2 minutes then washed in running tap water for a further 4 
minutes. Tissue was then dehydrated through ascending concentrations of ethanol (50%, 85%, 95% 
and 100%) for 4 minutes and placed in xylene for 4 minutes. Slides were coverslipped using DPX. 
2.4.4  Immunohistochemistry 
 
Immunohistochemistry staining for apoptosis, CD68, αSMA, TGF-β1 and podocin were performed. 
These stains were performed to identify cell death, inflammatory cell infiltration, ongoing fibrosis 
(both αSMA and TGF-β1) and podocyte damage respectively. Podocin and ApopTag protocols were 
only carried out on kidney sections; whereas all other immunohistochemical stains were performed on 
both cardiac and renal tissue. 
The CD68, αSMA, podocin and TGF-β1 protocols were identical beyond the use of specific primary 
and secondary antibodies; hence the protocol is described once, dilutions are described in Table 2. 
Tissue known to express antigens to the primary antibodies were stained using the protocol as a basic 
positive antibody control. For accurate and specific positive primary antibody controls, ELISA studies 
or western blot should be performed with the purified antigen specific to the primary antibody; which 
was not an option in this laboratory (Burry, 2011).  Secondary antibody controls, which test the 
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specificity of the secondary antibody, were performed by performing the immunostaining protocol on 
a tissue section, as described in 2.4.4.2, however the primary antibody was omitted (Burry, 2011).   
2.4.4.1  Apoptag 
 
Identification of apoptotic cells by the indirect TUNEL method was performed using an ApopTag 
staining kit (Merck Millipore, Billerica, USA).  Tissue was dewaxed in 2 xylene washes for 5 minutes 
each then rehydrated through a series of ethanol washes (100% twice, 95%, 85% twice and 50% for 4 
minutes each). Slides were then washed in phosphate-buffered saline (PBS) (pH 7.4) for 5 minutes. A 
Dako pen was then used to create a well around the tissue and a freshly prepared dilution of a 
proteinase K solution (20µg/ml) was pipetted onto the tissue and incubated for 10 minutes at room 
temperature (RT). Slides were washed in ddH₂O twice for two minutes then tissue was incubated for 
10 minutes with 3% hydrogen peroxide, diluted with PBS, to remove endogenous peroxidases. 
Slides were then washed in PBS twice for 5 minutes each, PBS is then removed from the slide and 
17.5µL of equilibrium buffer was added to the tissue; a coverslip was then placed on the slide to 
spread the reagent over the tissue and was left to incubate for 10 minutes. The coverslip and 
equilibrium buffer was removed and 12.5µL solution of working strength terminal deoxynucletidyl 
(TdT) enzyme (diluted 3:7 in the Apoptag kit reaction buffer) was added to the tissue. Slides were 
then cover slipped and placed in a humidified chamber at 37°C for 60 minutes.  
The coverslip and TdT solution was removed then the tissue well was filled with ddH₂O-diluted 
(1:35) stop/wash buffer then incubated in a humidified chamber at 37°C for 30 minutes. Slides were 
washed in PBS thrice for 2 minute each. PBS was removed from the slide and 17.5µL of anti-
digoxigenin conjugate was placed in the tissue well which was then coverslipped and incubated at 
room temperature for 30 minutes.  
After coverslip removal, slides were washed in 4 changes of PBS for 2 minutes each and a 200μL 
volume of freshly prepared diaminobenzidine (DAB) peroxidase substrate (Vector Laboratories, 
Burlingame, USA) was used to cover the tissue and incubated for 10 minutes. The DAB peroxidase 
substrate was prepared by adding 2 drops of kit buffer stock solution, 4 drops of kit DAB stock 
solution and 2 drops of the kit hydrogen peroxide solution to 5ml of dH₂O. Slides were taken through 
3 washes of ddH₂O for two minutes each, counterstained in Gill’s number 2 haematoxylin for 15s. 
Slides were rinsed in cold tap running water for 5 minutes before the tissue was dehydrated in ethanol 
washes (50%, 85%, 95% and 100% twice) for 3 minutes each. Slides were then cleared in xylene for 
at least 30 seconds and coverslipped using DPX as a mountant. 
Placental tissue sections were used as positive control for the ApopTag staining kit. The specificity of 
the anti-digoxigenin conjugate was also tested with placental tissue; the protocol used to do so was 
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identical to the ApopTag protocol, however the Tdt enzyme was not added to the tissue section rather 
the sections were incubated with PBS.  
2.4.4.2  CD68, TGFβ, αSMA and Podocin   
 
Paraffin embedded sections were dewaxed through two 5 minute xylene washes, then placed in 100% 
ethanol wash for 4 minutes. Tissue was then rehydrated by moving slides through a series of ethanol 
washes (95%, 85% and 50%) for 2 minutes each, before being placed in a PBS wash for 3 minutes. 
Slides were then incubated in sodium citrate buffer (pH 6) for 30 minutes at 95°C for the purpose of 
heat induced antigen retrieval (D'Amico et al., 2009). 
Slides, still in the citrate buffer, were cooled at RT for 20 minutes then placed through two 5 minute 
PBS washes. Dako pen was used to create a tissue well as described in the PAS protocol. Slides were 
then incubated for 2 hours in a one-fifth dilution (in ddH2O) of plant-based animal-free blocker, then a 
10 minute incubation was carried out using a 1% BSA PBS solution as a further blocking step. 
Optimal dilutions of primary antibodies (diluted in a 1% BSA PBS solution), as described for each 
staining procedure in Table 2, were then added on to the tissue, coverslipped and slides were 
incubated in a humidified chamber at 4°C overnight.  
After primary antibody incubation slides were washed twice in PBS for 10 minutes each, endogenous 
peroxidases were then quenched by a 10 minute tissue incubation of a 0.3% H₂O₂ PBS solution. 
Slides were washed thrice in PBS for 5 minutes each, after which appropriate dilution (in a 1% BSA 
PBS solution) of horseradish peroxidase labelled secondary antibody, as described in Table 2, was 
added to the tissue well and left to incubate for 90 minutes. Slides were once again washed thrice in 
PBS for 5 minutes each, and then tissue wells were filled with a freshly prepared DAB peroxidase 
substrate solution and left to incubate until an adequate colour change was achieved. Slides were then 
placed in a ddH₂O wash for 5 minutes before being counterstained with haematoxylin for 10 seconds 
and left in running tap water for 2 minutes. The tissue was then dehydrated using ascending 
concentrations of ethanol washes (50%, 85% and 95%) for 2 minutes each before being placed in 










Rat spleen was used as positive controls for both CD68 and α-SMA primary antibodies. Rat prostate 
sections were used as a positive for the TGF-β1 primary antibody. A normotensive kidney tissue was 
used as a positive control for podocin staining. Secondary antibody controls were performed by 
incubating the tissue section with 1% BSA PBS instead of the primary antibody. 
2.4.5  Semi quantitative analysis  
2.4.5.1  Tissue visualisation and image capture 
 
Slides stained with picrosirius red and CD68 and Apoptag immunohistochemistry techniques were 
scanned at 20 x magnifications by an Aperio Scanscope CS2 image capture device (Leica Biosystems, 
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Table 2: Dilutions of Primary and Secondary Antibodies for Immunohistochemistry Staining 
Protocols  
   
36 
 
Slides stained with H&E, PAS, and podocin, αSMA and TGF-β immunohistochemistry techniques 
were observed using an Eclipse Ni-E upright microscope (Nikon Corporation, Tokyo, Japan). Images 
of areas of interest were taken using a Digital Sight DS-U3 microscope camera (Nikon Corporation, 
Tokyo, Japan) using NIS-Elements imaging software (Nikon Corporation, Tokyo, Japan).  
The large area scanning tool of NIS-Elements imaging software was used to capture images of 
myocardium across the left ventricular wall for both cardiac TGF-β and α-SMA stained sections; each 
cardiac section captured provided 30 fields of 20x magnification. A similar technique was used for 
capturing images of renal TGF- β stained sections which contained a mixture of cortex and medulla, 
whereas α-SMA areas scanned were either exclusively cortex or medulla creating two images for 
analysis per kidney slide. Each scan of renal tissue provided 15 fields of 20x magnification. 
Representative micrographs demonstrating tissue structure in the presence of H&E and PAS staining 
were photographed using NIS-Elements imaging software through the Eclipse Ni-E upright 
microscope, the images were then auto-balanced as a whole image using Adobe Photoshop CS3 
(Adobe, San Jose, USA).   
2.4.5.2  Picrosirius Red  
 
Quantitative analysis of fibrosis was carried out by analysing the proportion of picrosirius red staining 
in a tissue section. This was performed by using the Aperio Imagescope software v.12.3 package 
(Leica Biosystems, Nussloch, Germany). The renal cortical region was selected by using a 
combination of the ‘free hand pen’ and the ‘negative free hand pen’ macro to exclude the non-cortical 
area. This exclusion allowed standardisation between tissue sections analysed, this was required as the 
ratio of cortex area varied between tissue sections. The optimised Positive Pixel count v.9 algorithm 
within Aperio Imagescope software was then used to quantify the total number of pixels as well as the 
number of red pixels per tissue section; allowing the percentage of red pixels to be analysed.  
In cardiac sections only myocardium which contributed to the ventricular walls surrounding the left 
ventricle was selected for analysis; the myocardium exclusively contributing to right ventricular wall 
was excluded prior to analysis. The right ventricle does not experience afterload stress in systemic 
hypertension, unlike the left ventricle, so is unlikely to develop hypertensive change (Diamond et al., 
2005). Variable cytoplasmic staining of cardiomyocytes by the picrosirius stain, previously 
encountered in other research (Dolber et al., 1987), required tuning of the algorithm ( changing the 
hue saturation requirements) to allow specific collagen fibre recognition. However this reduced the 
sensitivity of the algorithm to collagen fibres.  
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2.4.5.3  Periodic acid-Schiff   
 
Slides stained with PAS were blinded to the examiner by having had identifying marking occluded 
using tape; the slides were then shuffled and were assigned a number from 1 to 24. The slides were 
then analysed under an upright light microscope by subjectively grading 90-140 individual glomeruli 
per slide by the level of glomerulosclerosis. The grades given to glomeruli were 0, 1, 2, 3 and 4 and 
were assigned as described in the caption of Figure 2.3. The number of glomeruli assigned each grade 
was recorded, this data was then used to calculate a glomerulosclerotic index (GSI) using the formula 
described in Figure 2.4 for each kidney (Saito et al., 1987).  The blinding tape was then removed so 
the GSI values could be taken forth to analysis.  
 
Figure 2.2: Determination of Glomerular Stage for Glomerulosclerotic Index (GSI) 
Periodic acid Schiff reaction (PAS) staining was performed on renal tissue sections. Basement 
membranes and the mesangial matrix are stained magenta with the use of PAS staining, expansion of 
both structures within the glomerular tuft are characteristic of glomerulosclerosis. Staging of 
glomerulosclerosis in individual glomeruli was performed subjectively by estimating the proportion of 
the glomerular tuft occupied by sclerosis. Glomeruli were assigned values as followed: Grade 0 (A), 
no change; Grade 1 (B), sclerotic area more than 10% but less than 25% of the glomerular tuft; Grade 
2 (C), sclerotic area exceeding 25% of the glomerular tuft but less than 50%; Grade 3 (D), sclerotic 
area exceeds 50% of the glomerular tuft but does not exceed 75% (global sclerosis); Grade 4 (E), 
global sclerosis. Scale bars represent 50μm. 
 
 
A B C 
D E 






N denotes the number of glomeruli, whereas the subscript denotes the sclerotic grade. The subscripts 
are as follows: 0 is grade 0, 1 is grade 1 etc. Adapted from Saito et al. (Saito et al., 1987) 
 
2.4.5.4  Apoptag  
 
ApopTag staining identifies apoptotic cells. The analysis of ApopTag immunohistochemistry was 
carried out using the Aperio Imagescope software package. The renal cortex was exclusively selected, 
for reasons described in section 2.4.5.2, by using a combination of the ‘free hand pen’ and the 
‘negative free hand pen’ macro. The Nuclear Count v.9 algorithm was then used to detect DAB-
stained cells in the tissue section. Only cells of 2+ and 3+ staining intensity were considered 
positively stained for apoptosis and taken for analysis. Imagescope also quantified the area analysed, 
allowing for the calculation of positive cells per mm
2
, the value taken for analysis. 
2.4.5.5  CD68  
 
CD68 is a protein highly enriched in macrophages; immunostaining with anti-CD68 antibody can 
therefore identify these inflammatory cells (Gottfried et al., 2008). CD68 analysis was attempted with 
the Imagescope software package using the Nuclear Count v.9 algorithm, as with ApopTag analysis, 
however was abandoned due to variable endothelial staining. CD68 expression has been confirmed in 
endothelium amongst other cells not immediately involved in an inflammatory response (Gottfried et 
al., 2008). Imagescope was then subsequently used for cell counting after blinding was performed. 
The ‘free hand pen’ allowed for selection of an area and cells considered potential macrophages were 
counted with the counting tool. Cells were considered macrophages if they were strongly DAB 
stained and did not encircle a lumen (suggestive of endothelium). Imagescope automatically 
quantified the area selected with the ‘free hand pen’ allowing the manual calculation of cells per mm
2
; 
the value taken for analysis. 
2.4.5.6  α-SMA  
 
Myofibroblasts, the primary effector cells of fibrotic change, can be identified by α-SMA 
immunohistochemistry. Renal α-SMA analysis was attempted with Imagescope using the nuclear 
count algorithm, however this failed due to positive staining of vascular smooth muscle cells 
𝐺𝑆𝐼 =
1 × 𝑁1 + 2 × 𝑁2 + 3 × 𝑁3 + 4 × 𝑁4
𝑁0 + 𝑁1 + 𝑁2 + 𝑁3 + 𝑁4
 
Figure 2.3: Formula for Calculation of Glomerulosclerotic Index 
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(VSMCs) and variable staining of mesangial cells. Both cell types express α-SMA, however 
mesangial cells only seem to express α-SMA in states of renal pathology (Johnson et al., 1991).  
Manual cell counting was subsequently performed using ImageJ (National Institutes of Health, 
Bethesda, USA) after the source of the image were blinded to the examiner. Positively stained cell 
were not counted if they were present within the glomerular tuft or if the cell/cells formed a ring of 
positively stained tissue around a lumen; these cells were excluded due to the likelihood of them 
being mesangial or VSMCs respectively. The images identification was revealed to the examiner after 
all images were analysed and the number of positively stained cells within the tissue section was 
taken forward for analysis. Each image captured 15 fields of 20x magnification; thus captured a 
standard area for analysis. The scans of both the medulla and cortex were analysed separately in this 
fashion. 
Cardiac sections stained for α-SMA were analysed in exactly the same way as renal tissue, however 
the image captured 30 fields of 20x magnification. 
2.4.5.7  TGF-β1 and Podocin  
 
TGF-β1 is a pro-fibrotic signalling protein, whereas podocin is a podocyte specific protein. The 
analysis of tissue treated with TGF-β1 and podocin immunohistochemistry techniques were both 
performed by utilising the Imagescope software package. For anti-podocin antibody treated sections 
the glomeruli were isolated in the image by selecting the glomerular tuft present with the free hand 
pen. One glomerulus was randomly chosen from 6 different sections of the cortex and was captured 
x40 magnification. All tissue area in the x20 magnification images of anti-TGF-β1 antibody treated 
sections were selected as a region of interest. 
The Positive Pixel count v.9, optimised for detecting brown pixels, was used to quantify the 
proportion of DAB stained pixels in the tissue section of interest. The average proportion of positively 
stained pixels in the areas of interest was taken on to analysis.   
2.5  Statistical analysis 
 
All experimental data was analysed using the Prism v.6 software package (Graphpad, San Diego, 
USA). A Student t-test was used to compare variables across dietary groups (Standard diet vs I3C 
diet); this was used to identify if a pathological effect occurring in the I3C diet group. If a statistically 
significant effect was detected across dietary groups, all experimental groups were analysed in a two 
way analysis of variance (ANOVA) with a Bonferroni post hoc adjustment; this analysis was used to 
identify if a pathological effect was reduced with treatment.  
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Linear regression models were used to compare the association between blood pressure and other 
measured experimental variables for the whole set of data. If a strong linear association was detected 
linear regressions were compared between drug treatment groups to detect altered biological 
responses.  
Results were considered statistically significant if P<0.05. All values are expressed as a mean ± 
standard error of the mean (SEM).  
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Chapter 3:  Results 
  




3.1  Physiological Data  
3.1.1  Systolic Blood Pressure  
 
Figure 3.1: Systolic Blood Pressure (SBP) Measurements on Experimental Day 0 
Cyp1a1-Ren2 transgenic rats fed the I3C diet for 14 days had a higher pre-treatment SBP than rats on 
the standard diet. Rats in spironolactone and amlodipine treatment groups had higher SBP readings 
than the control animals in the I3C diet group.   vehicle control,  spironolactone;  
amlodipine. Data values represent an experimental group mean ± SEM; n=4 animals per group. 
ΨΨ
 
Statistical significance between diet groups (P<0.01). *P<0.05 from the I3C control group. **P<0.01 
from the I3C control group. 
 
SBP was significantly higher in the I3C diet group than the standard chow group on experimental day 
0 (130.7 ± 5.1mmHg vs 96.0 ± 2.2mmHg, P<0.01). As visualised in Figure 3.1 there were no 
significant differences between treatment groups in standard diet animals, however for rats on I3C 
chow there was a significantly higher SBP in both treatment groups as compared to control (control vs 
spironolactone, 113.7 ± 2.9 mmHg vs 135.0 ± 9.8 mmHg, P<0.05; control vs amlodipine, 113.7 ± 2.9 
mmHg vs 143.5 ± 4.7 mmHg, P<0.01). It is important to note that as treatment did not begin until 
experimental day 40; the observed difference in SBP between the hypertensive treatment groups was 
not due to pharmacological intervention. 
On day 85 SBP was once again collectively higher in the I3C groups as compared to standard diet 
groups, but to a much larger extent than at day 0 (171.3 ± 7.9 mmHg vs 96.3 ±2.8 mmHg, P<0.0001). 
Within the I3C diet group the rats treated with spironolactone appeared to have had a higher systolic 
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blood pressure than the control rats (Figure  3.2); however this result was not statistically significant 
(P=0.0913). No statistically significant differences in blood pressure were observed between the 
treatment groups within the diet divisions.  
 
 
Figure 3.2: Systolic Blood Pressure (SBP) on Experimental Day 85 
SBP was elevated collectively in the I3C diet group compared to the whole standard diet group; 
however there was no difference in SBP between treatment groups within dietary groupings.  
vehicle control,  spironolactone;  amlodipine. Data values represent an experimental group 
mean ± SEM; n=4 animals per group. 
ΨΨΨΨ
 Statistical significance across diet groups (P<0.0001).  
 
3.1.2  Weight 
 
Baseline weights did not differ between dietary groups (P=0.181). At day 84, the mean weight of rats 
in the standard diet group was 462.8 ± 5.7g , significantly higher than mean rat weight of the I3C diet 
group 397.3 ± 4.8g (P<0.0001); this difference is visualised by Figure 3.3. The average weight gain in 
each rat over the study period was higher in rats consuming only the standard rat chow compared 
those on the I3C diet (70.8 ± 3.4g vs 3.0 ± 4.4g respectively, P<0.0001). Mean weight gain did not 
differ between treatment divisions of the diet groups, seen in Figure 3.4.  
A linear regression of weight gain and blood pressure at day 85 was performed (Figure 3.5).  A strong 
linear relationship was detected between these two values (R
2
= 0.81); 81% of the variation of weight 
 
   
44 
 
gain is explained by the variation in the blood pressure at day 85, and vice versa. No differences of 
trends were observed when drug treatment groups were compared together. 
 
 
Figure 3.3: Comparison of Recorded Weights between Diet Groups from Experimental Days 0 to 84 
Weights in the standard diet group steadily increased from day 0, contrasting with the I3C group 
which recorded no significant weight gain from day 0 to 84. The differences in rat weight between 
diet groups peaked at day 84.  standard diet group;  I3C diet group. Data points represent 
dietary group mean ± SEM (n=12). 
ΨΨΨΨ
 Statistical significance across diet groups (P<0.0001). 
 
 
Figure 3.4: Weight Gain in Experimental Groups from Experimental Day 0 to Day 84 
Weight gain was significant higher in the standard diet group compared to the I3C diet group, 
however no significant differences were observed in treatment groups within the diet groups.  
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vehicle control,  spironolactone;  amlodipine. Data values represent an experimental group 
mean ± SEM; n=4 animals per group. 
ΨΨΨΨ




Figure 3.5: Linear regression of Weight Gain and Systolic Blood Pressure (SBP) at Experimental Day 
85 
The line represents the ‘line of best fit’ or the linear relationship which is apparent between SBP at 
experiment day 85 and rat weight gain from experimental days 0 to 84. Each data point represents an 
individual rat (n=24). R
2
=0.81. 
3.1.3  Urine Output  
 
Urine output was significantly higher in rats in the I3C diet group compared to standard chow (22.9 ± 
1.3 ml/12h vs 4.5 ± 0.4 ml/12h, p<0.0001). Rates of urine output did not differ significantly between 
treatment groups in either diet group, although urine output in the spironolactone group seemed to be 
larger than in the control group within rats assigned to the I3C diet (25.0 ± 2.7ml/12h vs 21.1 ± 
2.0ml/12h, P=0.21)  
A linear regression of urine output and systolic blood pressure on experiment day 85 revealed a strong 
linear association between the two variables (R
2
= 0.88), with 88% of variation in urine output 
explained by the variation in blood pressure (Figure 3.6). Treatment specific linear regressions 
suggested there was no altered urine output between treatment groups when SBP was taken into 
account.  




Figure 3.6: Linear Regression of Urine Output and Systolic Blood Pressure (SBP) at Experimental 
Day 85 
The line represents the ‘line of best fit’ or the linear relationship which is apparent between SBP at 




3.1.4  Proteinuria 
 
Proteinuria was significantly higher in the I3C dietary group compared to standard diet (376.8 ± 28.9 
mg/12hr vs 66.6±4.2 mg/12hr, P<0.0001). Proteinuria did not significantly differ between drug 
treatment groups in either dietary group, demonstrated in figure 3.7. Linear regression analysis was 
conducted on all proteinuria and day 85 SBP data, resulting in a moderately strong linear relationship 
being detected (R
2
=0.773). Linear regressions of the same nature, however comparing treatment 
specific groups, demonstrated that spironolactone may reduce total proteinuria when variations in 
systolic blood pressure were taken into account, as seen in Figure 3.8. A line of best fit analysis 
comparing total proteinuria and day 85 SBP, produced a much steeper slope with the vehicle control 
rat data compared the slope to spironolactone treated rat data; however this difference in slopes was 
not statistically significant (P=0.154).  




Figure 3.7: Proteinuria Excretion Amongst Experimental Groups 
Proteinuria was significantly higher amongst I3C diet rats compared to standard diet.  vehicle 
control,  spironolactone;  amlodipine. Data values represent an experimental group mean ± 
SEM; n=4 animals per group. 
ΨΨΨΨ




Figure 3.8: Linear Regressions of Proteinuria and Systolic Blood Pressure (SBP) at Experimental Day 
85 for Control and Spironolactone Treated Rats 
The gradient of the line of best fit is visibly steeper for control rats compared to spironolactone treated 
rats, however this difference was not statistically significant (P=0.154).  vehicle control data point, 
 vehicle control line of best fit,   spironolactone treated data point,  spironolactone treated line 
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of best fit. Each data point represents an indivdual rat (n=8 for each treatment group). R
2
 for control 
and spironolactone treated was 0.805 and 0.882 respectively.  
 
3.1.5  Left Ventricular Wall Thickness 
 
Both ventricular wall measurements, IVSW and LVPW thickness, were larger in the I3C diet group vs 
the standard diet group (P<0.0001 and P<0.05 respectively). No significant difference was observed 
in thickness of the LVPW between treatment groups in either diet group. Rats treated with 
spironolactone had increased IVSW thickness compared to control in the standard diet group (2.91 ± 
0.07 mm vs 2.50 ± 0.07 mm, P=0.0267), outlined in Figure 3.9; however this was not seen in the I3C 
diet group. No other differences in IVSW thickness were observed between the treatment divisions of 
the dietary groups. 
 
Figure 3.9: Intraventricular Septal Wall (IVSW) Thickness between Experimental Groups 
Cyp1a1-Ren2 transgenic rats within the spironolactone treatment arm of the standard diet group had a 
thicker IVSW than the standard diet control group.  vehicle control,  spironolactone,  
amlodipine. Data values represent an experimental group mean ± SEM; n=4 animals per group. 
statistical significance from the standard diet control group (P<0.05),
 ΨΨΨΨ
 statistical significance 
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3.1.6  Ejection Fraction  
 
There was no difference in left ventricular ejection fraction between diet groups (P= 0.79). 
3.2  Histological Data  
 
3.2.1  H&E Observations  
 
Pathological features, characteristic of hypertensive nephrosclerosis, were observed in renal sections 
isolated from animals in the I3C diet group (described in Figure 3.10). Examination of renal sections 
showed widespread glomerulosclerosis with a varying amount of glomerular tuft involvement within 
the sclerosed glomeruli. Dilated distal tubules, engorged with an eosinic substance, were observed 
throughout the renal cortex and medulla of rats within the I3C diet group. Renal sections from rats 
within the standard chow group had no obvious structural features suggestive of renal damage.  
The cardiac H&E stained sections did not have overt pathological features to distinguish tissue 
sections sourced from rats in the I3C and standard diet groups. Cardiomyocyte width seemed to be 
greater in the I3C diet group when compared to the standard diet group.  




Figure 3.10: Structural differences in renal and cardiac sections between standard and I3C diet 
groups demonstrated with H&E staining 
(A) and (B) are both micrographs of the renal cortex, (A) is from a rat in the standard diet group, (B) 
is from the I3C diet group. Image (A) has two glomeruli which are clearly distinct structures from the 
renal tubules. Proximal tubules, which have irregular ‘fluffy’ projections into their lumen, make up 
the bulk of the image. (B) demonstrates a typical pattern of renal cortex damage seen in an I3C diet 
animal. Glomeruli (arrows), unlike (A), can have varying degrees of sclerosis and may not be clearly 
defined from the other renal tissue. Dilated distal tubules (arrowheads) are also present. The image, 
compared to (A), is sparsely populated with proximal tubule. There are also areas of hypercellularity 
with no tissue definition, suggestive of fibrosis and inflammatory cell invasion. (C) and (D) are both 
micrographs of cardiac sections which have been taken in a transverse cellular plane; (C) is from 
taken from a standard diet rat, (D) an I3C fed rat. In (C) cardiomyocytes are separated from each 
other by small interstitial spaces with the presence of occasional capillaries. (D) follows the same 
basic structure, however individual cardiomyocytes seem to occupy a larger space; consequently less 
cardiomyocytes are seen in (D) compared to image (C). Scale bars represent 50μm. 
 
3.2.2  Picrosirius Red  
 
Picrosirius red staining was used to measure tissue changes in collagen accumulation, suggestive of 
fibrosis. The proportion of pixels in the renal cortex, detailed in Figure 3.11, stained positive for 
picrosirius red staining, was higher in the I3C diet group compared to standard diet (21.2 ± 1.1% vs 
A B 
C D 
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16.0 ± 0.9%, P=0.0012). There was no statistically significant difference in picrosirius red staining 
between treatment groups of either dietary group, however in the I3C diet group rats treated with 
spironolactone seemed to have a reduced proportion of positive pixels than vehicle control (19.5 ± 
1.2% vs 22.9 ± 2.8%, P=0.34). The proportion of picrosirius red staining in the I3C control group was 
increased compared to the standard diet control group (22.9 ± 2.8% vs 15.0 ± 0.8% P=0.01); no 
significant difference was seen between the spironolactone I3C and standard diet groups, nor was one 
seen for amlodipine groups. 
 Left ventricular myocardium, as with the renal cortex, had a larger area staining picrosirius red 
positive in the I3C diet group compared to standard diet, but this result was not significantly different 
(2.7 ± 0.1% vs 2.2 ± 0.3%, P=0.106).  
 
 
Figure 3.11: Proportion of Renal Cortex Stained Picrosirius Red positive in Experimental Groups 
The proportion of positive pixels was increased in the I3C dietary group compared to those on a 
standard diet.  vehicle control,  spironolactone;  amlodipine. Data values represent an 
experimental group mean ± SEM; n=4 animals per group. 
ΨΨ
 Statistical significance across diet 
groups (P<0.01). 
 
3.2.3  PAS Staining 
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GSI scores were higher amongst kidney sections sourced from rats in the I3C dietary group compared 
to standard diet animals (2.55 ± 0.09 vs 1.48 ± 0.09, P<0.0001). No differences in GSI scores were 
observed between treatment groups within the study dietary divisions.  
3.3  Immunohistochemistry Semi-quantification  
 
3.3.1  CD68 
 
Levels of macrophage infiltration described as macrophage cells per mm
2
 were significantly elevated 
in sections of the renal cortex sourced from I3C rats compared to standard diet rats (55.0 ± 12.9 
cells/mm
2
 vs 4.1 ± 1.0 cells/mm
2
, P=0.0007). No significant difference was found between treatment 
groups of the dietary groups. However a striking reduction in macrophages per mm
2 
was observed in 
the I3C spironolactone treatment group compared to control, though this result was not significant 
(27.2 ± 18.2 cells/mm
2
 vs 56.8 ± 12.6 cells/mm
2
, P=0.35). A very apparent opposite trend of 
increased renal cortex macrophage populations was seen in the I3C amlodipine group compared to 
control (80.8 ± 28.9 cells/mm
2
 vs 56.8 ± 12.6 cells/mm
2
 , P=0.54) but once again statistical 
significance was not achieved. These findings are outlined in figure 3.12, as well as micrographs of 
CD68 immunohistochemistry.  
There was no significant difference in the numbers of CD68 positive macrophage cells per mm
2
 in left 
ventricular myocardium between diet groups (P=0.6322).  




Figure 3.12: CD68 localisation in Control and Renal Cortex Sections and Quantification of 
Macrophages in the Renal Cortex 
The positive CD68 primary antibody control was performed in a splenic tissue section (A), which 
intensely stained resident macrophages. Secondary antibody controls, also performed in splenic tissue, 
showed faint background staining (B). Endothelium stained positively for CD68 (arrowheads), 
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eliminated these cells from analysis. Renal cortex tissue sourced from animals on the I3C diet was 
found to have macrophages (arrowheads) scattered in small groups throughout the tissue (D). Scale 
bars represent 50μm. 
(E) Renal cortex macrophage semi-quantification. Macrophages, identified by examiner judgement, 
were counted at x20 magnification.   vehicle control,  spironolactone,  amlodipine. 
Data values represent an experimental group mean ± SEM; n=4 animals per group. 
ΨΨΨ 
statistical 
significance across diet groups (P<0.001). 
3.3.2  α-SMA 
 
Myofibroblasts numbers were elevated in the I3C diet group compared to standard diet in both cortex 
(35.6 ± 8.8 cells per image vs 3.5 ± 1.2 cells per image respectively, P=0.0015) and medulla (18.3 ± 
3.6 cells per image vs 1.8 ± 0.7 cells per image respectively, P=0.0002). There was no significant 
difference in myofibroblast populations between dietary groups for cardiac sections.  
There were no statistically significant differences in myofibroblasts numbers as a consequence of 
treatment within either the standard or I3C diet for both the renal cortex and medulla regions 
analysed. In the cortex (Figure  3.13), myofibroblasts populations were changed but not significantly 
elevated in either treatment group on the I3C diet (control vs spironolactone, 19.8 ± 6.2 cells per 
image vs 42.0 ± 23.7 cells per image, P=0.35; control vs amlodipine,  19.8 ± 6.2 cells per image vs 
45.0 ± 11.1 cells per image, P=0.25). 
 




Figure 3.13: α-SMA localisation in Control and Renal Cortex Sections and Quantification of 
Myofibroblasts in the Renal Cortex 
Positive primary antibody controls in were performed splenic tissue sections; clearly identifying two 
arterioles as α-SMA positive (A).  No arteriole staining was seen in the secondary antibody control 
(B). As α-SMA immunohistochemistry also stains vascular smooth muscle cells of arterioles and 
other vasculature (A & C) and glomerular mesangium (C); examiner judgement was required to 
exclude these cells from analysis for myofibroblast quantification.  In the cortex myofibroblasts were 
typically present in small patches, (D) shows a small grouping of myofibroblasts (arrowheads) 
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(E) Renal cortex myofibroblast semi-quantification. Myofibroblasts, identified by examiner 
judgement, were counted at x20 magnification. Images used for analysis were of a standard area 
(fifteen 20x fields).  vehicle control,  spironolactone,  amlodipine. Data values 
represent an experimental group mean ± SEM; n=4 animals per group. 
ΨΨ 
statistical significance 
across diet groups (P<0.01).  
 
3.3.3  Podocin, TGF-β and ApopTag 
 
No difference in either of these experimental variables was observed between standard and I3C 
dietary groups; suggesting there was no impact of hypertension on apoptotic cell concentration and 
podocin or TGF-β1 levels in the renal cortex. The same finding was seen in cardiac TGF-β1 staining. 
Figure 3.14 shows micrographs of tissue stained by these various immunohistochemical methods.  
 
 
Figure 3.14: Immunohistochemical micrographs showing examples of biomarker identification 
(A) shows a glomerulus with dense podocin antibody binding.  (B) is a micrograph of tissue following 
the use of an ApopTag Kit, tubule cells typically stained positive for apoptosis. (C) is cardiac tissue 
post TGF-β1 antibody staining, whereas (D) is renal tissue following the same procedure; both show 
non-specific staining throughout the tissue with areas of intensity in renal tubular cells. Scale bars 
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Chapter 4:     Discussion  
  
   
58 
 
This study demonstrated the key effects of elevated blood pressure on the heart and kidney in a rat 
model of chronic (85 days) hypertension. Hypertension was successfully induced by long term I3C 
(0.167% w/w) administration in the diet to male Cyp1a1-Ren2 transgenic rats. Physiological 
indicators of organ haemodynamic stress were seen to increase in hypertensive rats: urine output, 
proteinuria and left ventricular wall thickness all increased significantly in the I3C fed rats. 
Histological evidence of damage and immunohistochemistry indicators of ongoing damage were 
increased in the kidneys of hypertensive animals. Morphological indicators of cardiac remodelling 
and fibrosis were also identified in the I3C diet group; however there was no significant increase in 
any cardiac histological or immunohistochemical variables compared to standard diet rats. The 
aldosterone inhibiting effects of the MRA spironolactone were then compared to those of the direct 
vasodilating, calcium channel blocker amlodipine in the interventional part of this study. The study 
took care to use doses in rats which were therapeutically relevant to the treatment of human 
hypertension. Disappointingly neither spironolactone nor amlodipine had any significant effect on 
SBP in these hypertensive animals; nor did they have a significant effect on any other experimental 
variable measured. Trends of decreased interstitial fibrosis and macrophage infiltration were observed 
in the renal cortex after treatment of spironolactone. When blood pressure was taken into account, 
spironolactone non-significantly reduced levels of proteinuria. Unexpectedly amlodipine treatment 
produced non-significant increases in both macrophage and myofibroblast infiltration in the renal 
cortex of hypertensive animals. Spironolactone also seemed to increase myofibroblast appearance in 
the renal cortex.  
4.1  Blood Pressure  
 
Administration of the I3C diet to Cyp1a1-Ren2 rats modestly increased blood pressure at day 0 (14 
days after the onset of the I3C diet); chronic treatment continued to dramatically increase SBP at day 
85. Increases in blood pressure were much higher after two weeks of 0.167% I3C exposure in the pilot 
study performed by a lab group member and in studies by Peters et al. compared to the readings 
collected in this study (Peters et al., 2008; Peters et al., 2012). However day 85 SBP readings were 
consistent with 0.167% I3C induced hypertension. 
At day 0, SBP was increased in the spironolactone and amlodipine treatment groups compared to 
control amongst rats on the I3C diet; pharmacological intervention did not begin until experimental 
day 40. As explained in the methods these two experimental groups were previously exposed to the 
I3C diet for at least 2 weeks from 8 weeks of age, while the control group was not. Heijnen et al., has 
shown that I3C diet exposure to young (4 week old) Cyp1a1-Ren2 rats causes irreversible renal 
damage, leading to blood pressure elevation post withdrawal of the I3C diet (Heijnen et al., 2013; 
Heijnen et al., 2014); however in contrast to this study a higher dose of I3C was used (0.3%), and the 
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rats were exposed for 4 weeks. Perhaps this described renal damage may explain the variation in SBP 
at day 0 between treatment groups of hypertensive rats; however the normotensive amlodipine diet 
group was also previously exposed to the I3C, but did not have a sustained elevated SBP at day 0. It is 
possible that haemodynamic stress or systemic circulating ANGII, both elevated by the recommenced 
I3C diet, hastened the rise of blood pressure in the spironolactone and amlodipine groups due to a 
similar type of renal damage described in Heijnen et al.; but this early exposure may not have 
produced sufficient renal damage to allow the development of unprompted hypertension in the 
amlodipine standard diet group. 
Elevated blood pressure at experimental day 0 only persisted for the spironolactone I3C group at 
experimental day 85, though this difference was non-significant. SBP measurements at Day 85 were 
very similar between amlodipine and the control group amongst hypertensive rats. Both 
spironolactone and amlodipine have been shown to reduce blood pressure in other rat hypertensive 
models (Du et al., 2009; Ikeda et al., 2009). The expected result of this study would have been a 
reduction in blood pressure in both treatment groups compared to control; the failure of the study to 
achieve this could be due to a number of factors. The early I3C exposure, suggested to explain the 
variation seen in day 0 blood pressure may have biased the baseline indices. It is also possible that the 
doses of either pharmacological intervention administered were insufficient to instigate a reduction in 
blood pressure. Unfortunately it is not possible to determine the cause without repeating the 
experiment under different conditions.  
It should be noted that the current study used the recommended FDA allometric dosing method for 
translating a human dose into the equivalent rat dose. Allometric dosing is based on the comparative 
ratio of body surface areas between humans and the relevant animal model. An organism’s cellular 
metabolic rate is proportional to its surface area rather than its weight alone.  Consequently surface 
area is generally used to provide a measure by which to normalise metabolic rate and hence drug 
metabolism between species (Reagan-Shaw et al., 2008). A failing with allometric dosing however, is 
that gross measures in metabolic rate do not take into account nuances in catabolic enzymes, which 
can dramatically alter drug pharmokinetics across species. This failing has led to a large number of 
studies using high equivalent or supramaximal doses of drugs to ensure a therapeutic effect (Sharma 
et al., 2009). For example a study by Du et al., used almost 7 times the dose of amlodipine used in 
this study, while Ikeda et al., used 11 times the dose of spironolactone given here (Du et al., 2009; 
Ikeda et al., 2009). Therefore using the FDA conversion method, this is the human equivalent of 
dosing a human 7 and 11 times more than the recommended dose. Amongst the papers cited in this 
discussion, the oral doses of spironolactone used to reduce SBP in animal studies have ranged from 
2.5 times to 23 times the dose used in this study (Aldigier et al., 2005; Onozato et al., 2007).  
Consequently it is very possible that the doses applied in the current study, while equivalent to human 
therapeutic doses, may have been insufficient to have a beneficial effect in this transgenic rat strain. 
   
60 
 
Compared to humans, amlodipine is known to have a dramatically reduced half-life in rats (35 hours 
vs 3-7 hours respectively) (Stopher et al., 1988; Bhandary et al., 2013); this is due to the presence of 
two hepatic enzymes capable of breaking down amlodipine in rats, compared to only one enzyme in 
humans (Guengerich et al., 1986). Therefore in light of these studies, amlodipine may have only 
produced a transient antihypertensive effect on the rats in this study rather than a sustained impact; 
perhaps explaining the lack of reduction in day 85 SBP and consequently the unchanged study 
variables in the hypertensive amlodipine group compared to control. Spironolactone may have also 
faced pharmacokinetic issues similar to amlodipine, potentially reducing drug response; however a 
review of the current literature suggest a similar metabolism and plasma half-life of spironolactone, 
and of spironolactone’s active metabolites, between rats and humans (Gardiner et al., 1989; Kaukonen 
et al., 1998). 
4.2  Weight 
 
Average weight gain was remarkably higher in the standard diet group compared to rats on the I3C 
diet. Studies have consistently shown that I3C introduction to Cyp1a1-Ren2 transgenic rats can 
induce weight loss and deterioration of condition (Kantachuvesiri et al., 2001; Prieto et al., 2011). 
This observed effect is I3C feed dose-dependent, as is blood pressure: administration of a 0.3% I3C 
diet consistently causes weight loss (Mitchell et al., 2006; Ortiz et al., 2007; Prieto et al., 2011), 
whereas a 0.15% diet induces hypertension without weight loss (Mitchell et al., 2006; Huang et al., 
2012). This study used a 0.167% I3C diet, only two studies have previously used this concentration 
and consequently included weight data in publication. These studies had mixed outcomes, both used 3 
month old rats; a 2-week pilot study demonstrated that the 0.167% diet stunted growth and triggered 
weight loss (Peters et al., 2008). Subsequent research by the very same group however dismissed the 
pilot study findings by demonstrating that 4 week administration of 0.167% I3C diet had no effect on 
eventual rat weight, measured 3 weeks after diet discontinuation  (Peters et al., 2008; Peters et al., 
2012). Our own earlier pilot studies performed by a group member, found that a 0.167% I3C w/w diet 
did not stunt weight gain over a 2 week dosing period. The rats used in this extended study however 
clearly exhibited stunted weight gain; albeit not to the same extent as previously described in studies 
using the 0.3% I3C diet. 
The weight loss in the 0.3% I3C diet studies is consistently claimed to be a manifestation of malignant 
hypertension: sustained ANGII-dependant hypertension has been theorised to stimulate extracellular 
fluid loss due to pressure diuresis, a phenomenon touched on in section 4.3 (Mohring et al., 1975; 
Patterson et al., 2005). Therefore body fluid loss through a hypertensive induced diuresis may explain 
this stunted weight gain in the I3C group. However during this study diet aversion was noted amongst 
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I3C diet fed rats, this observation was not seen with their standard chow counterparts; restricted food 
intake is the most likely to be responsible for stunted weight gain.  
 
4.3  Urine volumes and Proteinuria 
 
Urine output was raised five-fold in hypertensive rats compared to normotensive rats, and a strong 
linear association of SBP and urine output was detected using a linear regression. These findings are 
consistent with pressure diuresis: increased blood pressure amplifies plasma filtration, resulting in an 
increased urine output (Guyton et al., 1972). Urine output was not significantly altered by any 
treatment group, though the spironolactone group trended to non-significant increase; however after 
taking variation of blood pressure into account, spironolactone did not increase urine output. Though 
spironolactone is a considered a mild diuretic, previous literature has shown that urine production is 
not elevated following spironolactone administration in rats (Bauersachs et al., 2000; Kambara et al., 
2003; Ortiz et al., 2007). 
Proteinuria is a predictive factor of renal decline across a range of renal diseases, reducing levels of 
proteinuria results in a slowing of renal functional decline (Peterson, 1995; Jafar et al., 2001). As 
discussed, proteinuria is a typical manifestation of podocyte damage, which can lead to 
glomerulosclerosis–related nephron loss, and the presence of filtered protein in renal tubules itself 
damaging (Nangaku, 2006; Zoja et al., 2014). Both of these factors provide powerful arguments for 
therapeutically attenuating proteinuria. In this study proteinuria was increased in hypertensive animals 
compared to the normotensive rats; as with urine output, a strong linear association was seen between 
SBP and proteinuria. This is consistent with the concept that haemodynamic stress damages 
podocytes; more haemodynamic stress should increase proteinuria (Bidani et al., 2004; Wang et al., 
2009).  No treatment group changed proteinuria output in the I3C group; though when SBP was taken 
into account a spironolactone-specific trend in decreased proteinuria was seen, however it was non-
significant.  
Multiple clinical studies have demonstrated a reduction in both albuminuria (a serum specific protein 
identified in the urine) and proteinuria with MRA use compared to first line antihypertensives, such as 
calcium channel blockers or ACEi’s, as a monotherapy in human hypertension (White et al., 2003; 
Williams et al., 2004). In animal studies proteinuria has been consistently reduced with MRA therapy 
(Nagase et al., 2006; Nagase et al., 2007; Shibata et al., 2008; Du et al., 2009; Ikeda et al., 2009); 
independently of the hypotensive effects of the MRA (Ortiz et al., 2007). Although a trend in 
proteinuria was not seen until SBP was taken into account, the non-significant effect of spironolactone 
in this study appears to be consistent with the literature. 
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4.4  Echocardiogram Variables  
 
As explored, LVH is triggered by chronically increased haemodynamic stretch stress exerted on the 
left ventricle (Drazner, 2011). Aligned with the pathology of HHD, echocardiographic analysis 
demonstrated that hypertensive I3C-fed rats had indeed developed a hypertrophic left ventricular 
response compared to the normotensive standard diet rats. None of the treatment groups demonstrated 
a reduction in left ventricular wall thickness.  
Clinically MRAs have been demonstrated to assist in reversing LVH when added to ACEi treatment, 
an effect associated with a decrease in blood pressure (Sato et al., 1999; Sato et al., 2002; Pitt et al., 
2003a). The most important predictor of left ventricular regression is a drop in blood pressure 
(Schmieder et al., 1998); thus these clinical findings may not represent a cardiac specific effect of 
MRAs, and certainly outlines a reason why no treatment specific regression was seen in this study. A 
study of SHRs has shown that if MRA intervention was instigated at the start of a hypertensive state, 
development of LVH can be prevented without a significant drop in blood pressure (Baldo et al., 
2011); supportive of MR-heart interaction. However prophylactic intervention with antihypertensives 
at the precise moment of hypertension onset is clinically irrelevant. 
Unusually IVSW thickness, a measure of left ventricular hypertrophy, was enlarged in the 
spironolactone treated normotensive group compared to control. These rats had never been exposed to 
the I3C diet and no published evidence documenting a similar response to spironolactone could be 
found.   
4.5  Histological and Immunohistochemical Findings  
4.5.1  Renal 
 
Renal fibrosis is generally characterised by the appearance of fibrosis of the glomerulus, 
glomerulosclerosis; and fibrosis of the interstitium, interstitial fibrosis (Nangaku, 2006). This 
deposition of collagen is further associated with inflammatory infiltration, and destruction of renal 
parenchyma typified histologically as tubular atrophy, as well as capillary depletion (Lee et al., 2010). 
Both patterns of fibrosis are consequences of renal damage, and both result in progressive ischaemic 
consequences for the interstitium. 
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4.5.1.1  Fibrosis  
 
The hypertensive animals had significantly higher levels of cortical fibrosis and glomerulosclerotic 
staging compared to the normotensive animals; consistent with the pathological findings of 
hypertensive nephrosclerosis (Rosario et al., 2006). None of the treatments abrogated these levels of 
fibrosis or glomerulosclerosis; however the spironolactone group had a non-significant reduction in 
fibrosis. Only the vehicle control group saw a significant increase in cortical fibrosis between its 
normotensive and hypertensive divisions, suggesting the hypertensive relationship with renal damage 
may have been modified with spironolactone or amlodipine intervention. Studies typically measure 
renal fibrosis as two separate measures, interstitial fibrosis and glomerulosclerotic staging; fibrosis 
measured in this study takes into account overall fibrosis, not distinguishing between 
glomerulosclerotic lesions and interstitial fibrosis, therefore is not directly analogous to interstitial 
fibrosis.  
Studies conducted in hypertensive rodents show a consistent reduction in both glomerulosclerotic 
staging and interstitial fibrosis with MRA therapy given throughout a period of induced hypertension 
(Blasi et al., 2003; Nagase et al., 2006; Onozato et al., 2007; Du et al., 2009; Ikeda et al., 2009). 
Amongst rats undergoing chronic ANGII infusion (8 weeks), a mechanistically similar model to the 
Cyp1a1-Ren2 transgenic rat, both interstitial fibrosis and levels of glomerulosclerotic change were 
reduced amongst spironolactone treated animals, despite no reduction in SBP (Lea et al., 2009).  
The bulk of studies investigating fibrotic change did not administer MRA therapy after a period of 
induced hypertension, as carried out in this study to simulate the treatment of established human 
hypertension. Rather therapy is generally given over the whole period of hypertension, perhaps 
explaining differences in the literature and this study. However two studies have looked at 
spironolactone administration after a period of untreated hypertension, both used the subtotal 
nephrectomy model. They also demonstrated a reduction in the progression of both 
glomerulosclerosis and interstitial fibrosis amongst spironolactone treated animals (Aldigier et al., 
2005; Piecha et al., 2008). The spironolactone dose used by Piecha et al., was less than double the one 
utilised in this current study, however Aldigier et al., used a dose more than 20 times the daily dose 
used in this study; this increased dosing likely explains the inconsistences between these studies and 
the results detailed in this thesis.  
4.5.1.2  Inflammation 
 
Inflammatory pathways are stimulated in the event of cellular or tissue damage; in this study 
inflammatory cell infiltrate has been used as a surrogate measure of ongoing damage (Medzhitov, 
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2010). Renal cortex macrophage infiltration in the hypertensive rats eclipsed the levels seen in rats on 
the standard diet. No intervention treatment significantly reduced inflammatory cell infiltration, 
however hypertensive spironolactone treated rats had a non-significant reduction in cortical 
macrophages compared to the hypertensive control group.  
Hypertension induced by DOCA or aldosterone infusion (accompanied by uninephrectomy and salt 
treatment) is associated with macrophage infiltration into the renal interstitium (Blasi et al., 2003; 
Klanke et al., 2008); hypertension induced by non-mineralocorticoid mechanisms also mimics this 
result (Ikeda et al., 2009). In all of these hypertensive situations, MRA treatment abrogated 
macrophage infiltration. In Klanke et al., blood pressure was not decreased with spironolactone 
intervention, however macrophage infiltration was attenuated; this study also demonstrated that 
antihypertensive therapy, which dramatically reduced blood pressure, also reduced macrophage 
infiltration to a similar level as MRA therapy (Klanke et al., 2008). In other studies MRAs have also 
decreased SBP as well as reducing macrophage infiltration (Blasi et al., 2003; Ikeda et al., 2009). 
Comparison studies have shown that while MR-independent pharmacological intervention can reduce 
blood pressure to an equivalent level as that obtained with spironolactone, MRA-independent 
approaches were found to be inferior to spironolactone at reducing macrophage infiltration (Ikeda et 
al., 2009). Therefore two of these studies demonstrate a reduction in renal macrophage infiltration 
with spironolactone use independently of blood pressure reductions, however it must be noted that the 
spironolactone dose in both studies was 11 times the dose used in this study (Ikeda et al., 2009) 
(Klanke et al., 2008). Once again, this suggests that although the dose of spironolactone used was an 
appropriate prescription for clinical monotherapy in hypertension, the translated dose used in the 
current study may have proved ineffective in the rat, and a higher dose may have led to a significant 
reduction in cortex inflammation.  
4.5.1.3  Myofibroblast populations  
 
Myofibroblasts are the primary effector cells of interstitial fibrosis (Falke et al., 2015); they have been 
identified and quantified in this study as a measure of ongoing fibrosis. Myofibroblast populations 
were increased in the renal cortex with hypertension. Animals subjected to treatment with 
spironolactone or amlodipine appeared to have higher numbers than control, however this was not 
significant in either treatment group. 
Few studies have looked at myofibroblast populations in the context of using MRA treatment to 
abrogate hypertensive damage; in these studies immunohistochemical staining and western blot 
analysis have shown that both eplerenone and spironolactone produce a reduction in α-SMA levels 
(Ikeda et al., 2009)(Piecha et al., 2008). As previously mentioned, the spironolactone dose in Ikeda et 
al., was 11 times the current study’s dose, however the dose used in Piecha et al., was less than 
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double. MRA therapy has also been shown to reduce renal α-SMA interstitial expression in 
circumstances of renal injury caused by insults other than haemodynamic stress (Kramer et al., 2007; 
Chen et al., 2013; Nielsen et al., 2013). Nevertheless the current study’s findings appear to be 
inconsistent with previous published results. 
4.5.1.4  Podocin, Apoptag and TGF-β1 Immunohistochemistry  
 
No significant changes were seen in podocin staining density as a consequence of hypertensive 
induction or treatment in this animal study. Podocin is a protein expressed by podocytes, reduced 
expression can be used to indicate podocyte damage (Yang et al., 2010; Yao et al., 2014). Similarly 
TGF-β1 antibody staining, used as a measure of tissue fibrotic signalling, as well as ApopTag staining, 
used to quantify cell numbers undergoing apoptosis, were both unchanged across diet groups.  
Apoptosis is seldom studied in chronic hypertensive situations, however one study assessing apoptosis 
in renal tissue was found. Transgenic hypertensive rats overexpressing angiotensinogen were found to 
have reduced levels of apoptosis in the renal cortex when blood pressure was pharmacologically 
reduced (Liu et al., 2009). Podocin expression is also understudied in hypertensive states. One human 
study has shown glomerular podocin mRNA levels, a measure of podocin expression, have been 
shown to decrease in hypertensive nephrosclerosis (Wang et al., 2009). In contrast to apoptosis and 
podocin, renal TGF-β1 levels are regularly studied; TGF-β1 levels are consistently found to increase 
with induced hypertension (Onozato et al., 2007; Ikeda et al., 2009; Miana et al., 2011). 
The estimation of relative podocin and TGF-β1 levels was performed by pixel analysis, where DAB 
pixel intensity was used to identify ‘positive pixels’. The DAB chromogen does not follow the Beer-
Lambert law, meaning that the concentration of DAB staining is not accurately reflected in staining 
intensity (van der Loos, 2008); therefore DAB pixel analysis findings may not have had any relation 
to protein levels. This nuance may explain why TGF-β1 staining was not increased amongst kidneys 
from hypertensive rats; perhaps the use of a different chromogen or another analysis technique such as 
western blotting may have changed this study’s findings.   
4.5.2  Cardiac 
 
This study showed no difference in cardiac histological or immunohistochemical variables between 
the hypertensive and normotensive groups; suggesting there were no detectable pathological effects 
attributable to hypertension in this study. Consequently the protective effect of interventional therapy 
could not be measured in this study. Cardiac fibrosis has been clearly demonstrated in multiple 
models of hypertension (Brilla et al., 1993; Lal et al., 2003). A trend of increased cardiac fibrosis was 
seen in the I3C fed group compared to rats administered the standard diet; however the large variation 
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in levels of fibrotic deposition in the standard diet group led to a non-significant difference being 
found between the dietary groups.  
Increased levels of TGF-β1 are also often demonstrated in cardiac tissue of ANGII instigated 
hypertension models, however TGF-β1’s association with hypertension is inconsistent amongst other 
rat models (Lijnen et al., 2000; Lea et al., 2009). With these studies not showing a consistent increase 
in cardiac TGF-β1 levels, perhaps it was not unexpected that no difference was found in this study.  
The mechanisms of hypertension-induced cardiac macrophage infiltration and myofibroblast 
populations have not been well explored. One recent study has evaluated the role of macrophages in a 
salt-sensitive hypertensive rat model, showing that macrophages do indeed invade the myocardium 
during chronic hypertension, and that a reduction of macrophage infiltration reduces progression of 
HHD (Kain et al., 2016). Hearts from SHRs have been demonstrated to have higher levels of α-SMA 
in cardiac tissue compared to non SHR normotensive rats (Lekgabe et al., 2005). The results in this 
thesis are not supportive of either of these findings. While performing the cell counting technique 
described in the methods (Sections 2.4.5.5 & 2.4.5.6) the identification of suspected macrophages and 
myofibroblasts was a relatively rare occurrence in the myocardium compared to the renal cortex; 
these smaller numbers may have skewed results due to chance distribution throughout the 
myocardium, perhaps if a larger area was analysed a significant difference could have been detected.  
4.7  Methodological Evaluation and Limitations of this Study 
 
The studies performed in this Honours thesis had some unavoidable limitations imposed on the 
project that should be considered in the interpretation of the findings presented. 
 The Cyp1a1-Ren2 transgenic animal breeding programme had been initiated prior to the start 
of the study under an animal ethics approval in order to deliver sufficient numbers of male 
rats to order for this honours project. As animal numbers were restricted both by availability, 
breeding time and by the ethics approval granted, one of the limitations of this study was the 
need to reuse animals that had been previously exposed for a brief period to the I3C diet at the 
original study onset. The study was consequently unable to use rats which were treated 
uniformly, potentially compromising comparisons to the control group; reducing internal 
validity. Unfortunately as explained in the methods section and earlier in the discussion, this 
was due to an unavoidable withdrawal from the initial plan due to stress concerns. The study  
was then recommenced with the existing rats as an exploratory study.  
 
 Blood pressure measurements were only taken twice over the duration of the study. More 
serial blood pressure measurements would have given a more accurate interpretation of the 
   
67 
 
impact of the I3C diet and the drug treatments on blood pressure. Unfortunately due to 
limitations of animal handler availability this was not possible.  
 
 The study proved underpowered to detect an association between groups with a n=4 number 
of experimental animals per group. While the original study design had been intended to be 
sufficiently powered with an original experimental group number of n=6, this number had to 
be reduced due to workload constraints on the laboratory from this study being unexpectedly 
delayed. The options at the point of recommencing the study were to perform an exploratory 
study as conducted here or simply euthanize the animals. An a priori calculation using the G-
power software designed by Faul et al. was used to calculate estimated sample size required 
for this study (Faul et al., 2007); this was based on the effect size of the reduction of CD68 
positive cells in the renal cortex amongst hypertensive animals treated with spironolactone 
compared to control. This was the largest effect size found in this study. The a priori test 
estimated that if the data was to be analysed using a special ANOVA technique (a category 
which includes two way ANOVAs) the n required to find a significant difference would be 
13; more than 3 times the animals per group in this study. Therefore sufficient power was 
significantly out of reach for this study, in both its final and originally intended form.  
 
 The statistical methods for analysis were unlikely to be appropriate; a test for normality was 
unavailable for an n of 4. A two-way ANOVA, which assumes normality, may have made 
inaccurate comparison when determining differences between treatment groups; however no 
other statistical analysis was found to fit this study design. Indeed as discussed above in the 
context of power, another statistical technique may have been more suitable for deciphering 
differences amongst groups with small sample sizes as used in this study.  
 
 As discussed in section 4.1, allometric scaling is an established system for calculating inter-
species drug doses; however it has limitations, as explored with the pharmacokinetics of 
amlodipine. It seems studies which have had clear benefits with spironolactone administration 
have all used supratherapeutic doses; suggesting that the spironolactone dose in this study 
may have been too small to meter out an effect, perhaps due to an unknown rat-specific 
pharmacokinetic (or pharmacodynamic) factors. However as well as being a limitation, this 
relatively low dosing of spironolactone is also a strength; assuming a large pharmacokinetic 
difference and then using large equivalent doses of pharmaceuticals has the potential to 
grossly exaggerate the benefits of a drug. Sidestepping these pharmacokinetic issues by the 
use of implantable osmotic pumps, which deliver a continuous infusion of pharmacological 
agents, was considered; however none of the pumps available provided a sufficiently long 
release to meet the dosing duration requirements of this study.  




4.8  Conclusions  
 
No clear findings on spironolactone use in a hypertensive rat model have been reported by this study; 
however non-significant associations consistent with existing literature have been identified. Many 
other beneficial findings of spironolactone from other studies were not reproduced in this study’s 
findings. As discussed in section 4.7 the internal validity of this study was compromised, in addition 
the study was underpowered to successfully identify associations. Both these factors severely limit the 
implications of the results. However this project had several strengths relating to similarities to the 
treatment of human hypertension, not often replicated in many animal studies: drug treatment was 
initiated after a period of hypertension, and use of drug dosing relatable to human treatment. Overall 
this study brings no conclusions forth to contribute to the existing literature, although this study may 
suggest that using human-equivalent doses of a MRA in hypertension results in few associated 
cardiorenal benefits in a rodent model.  
 
4.9  Directions for Future Studies 
 
This study unfortunately did not find any results to build on; rather these directions are based on 
inspection on the current state of the literature on mineralocorticoid receptor antagonists. There is 
currently a wealth of animal literature which supports the cardiorenal benefits of MRAs; however 
more avenues need to be explored. 
 Studies are needed on the pharmacokinetics and pharmacodynamics of MR’s to allow suitable 
animal dosing of MRA therapy which is somewhat relatable to human treatment.  Piecha et 
al., notes that in a pilot study exploring rat dosing a 80mg/kg dose of spironolactone (almost 
10 fold higher than this study’s dose) was fatal in 80% of rats when combined with a high 
dose of an ARB; this was no longer the case with a 15mg/kg dose used in the final study 
(Piecha et al., 2008). Most studies discussed in this thesis used more than this 80mg/kg dose; 
therefore if used in combination with a high dose ARB these studies could have had excessive 
mortality rates. If these commonly used high equivalent doses are potentially toxic, they are 
unlikely to be relatable to human doses; therefore studies which detail appropriate dosing 
schedules for rats would assist animal studies a great deal in their goal of being translatable.   
 Eplerenone is more tolerable than spironolactone; this is an important factor to consider when 
the ultimate goal of research is to be translated to clinical intervention. As hypertension is an 
asymptomatic condition, patients are unlikely to tolerate spironolactone’s androgen blocking 
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side-effects for no detectable benefit (Osterberg et al., 2005; Munger et al., 2007). The mantra 
‘Drugs don’t work in patients who don’t take them’ spells out the consequences of poor 
tolerability (Osterberg et al., 2005). Therefore it is more pertinent to study the MR blocking 
effect of eplerenone in hypertension rather than spironolactone, as eplerenone will likely have 
higher levels of adherence in the potential patient population. 
 Antihypertensive drug classes are often combined to ensure optimal blood pressure control. 
MRAs will be no different, therefore animal studies should also be performed with 
combination treatment to inspect for optimal cardiorenal benefit.  
 The impact of aldosterone on cardiac and renal damage has been routinely described with a 
variety of animal models; however emerging evidence has vindicated MR signalling in the 
development of vascular remodelling (Jaffe et al., 2010; Calvier et al., 2013; Pruthi et al., 
2014). Vascular remodelling increases vascular resistance, therefore MRA therapy has the 
potential to prevent, or even regress, the vascular changes which underlie hypertensive states 
i.e. both essential and isolated systolic hypertension (Mulvany, 2012).  
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